var title_f25_2_25632="Mesothelioma MRI III";
var content_f25_2_25632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma with hemorrhagic pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A liquid-liquid level is demonstrated on a sagittal T1- weighted image (arrows), most likely representing a hematocrit effect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25632=[""].join("\n");
var outline_f25_2_25632=null;
var title_f25_2_25633="Vulvar papillomatosis papules";
var content_f25_2_25633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Vulvar papillomatosis papules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) On the inner edge of the labia minora are variably sized yellow papules. These are normal sebaceous glands-sebaceous hyperplasia. Papillomatosis (B) On either side of the hymenal ring are obvious filiform papules filling the whole area. This is vulvar papillomatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fisher, BK, Margesson, LJ. Genital Skin Disorders: Diagnosis and Treatment. Mosby, St. Louis, Missouri 1998. p.104. Copyright &copy; 1998 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25633=[""].join("\n");
var outline_f25_2_25633=null;
var title_f25_2_25634="MTC surgical specimen";
var content_f25_2_25634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Medullary thyroid cancer: Surgical specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathological specimen of bilateral and multicentric medullary thyroid cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Expert Review of Endocrinology &amp; Metabolism, September 2009, Vol. 4, No. 5, Pages 443-465 with permission of Expert Reviews Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25634=[""].join("\n");
var outline_f25_2_25634=null;
var title_f25_2_25635="Apical 4 chamber echo vegetations mitral valve";
var content_f25_2_25635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber echocardiogram showing vegetations on the mitral valve in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber views from the transthoracic echocardiography show bulky vegetations on the mitral valve (arrows). These images have been captured digitally and are displayed in quadrant screen format. In spite of insensitivity for smaller vegetations, precordial imaging is often effective for the pupose of imaging vegetations.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; TV: tricuspid valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25635=[""].join("\n");
var outline_f25_2_25635=null;
var title_f25_2_25636="Pentoxifylline: Patient drug information";
var content_f25_2_25636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentoxifylline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     see \"Pentoxifylline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35316?source=see_link\">",
"     see \"Pentoxifylline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TRENtal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pentoxifylline SR;",
"     </li>",
"     <li>",
"      Trental&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, numbness, and tingling in the legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentoxifylline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent bleeding problem in your brain or in the retina of your eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking theophylline, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10965 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25636=[""].join("\n");
var outline_f25_2_25636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208250\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208251\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020583\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020585\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020584\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020589\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020590\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020592\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020587\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020588\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020593\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020594\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=related_link\">",
"      Pentoxifylline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35316?source=related_link\">",
"      Pentoxifylline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25637="Purine nucleoside phosphorylase deficiency";
var content_f25_2_25637=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Purine nucleoside phosphorylase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25637/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25637/contributors\">",
"     Arye Rubinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25637/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25637/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25637/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25637/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/2/25637/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine nucleoside phosphorylase deficiency (PNP deficiency, MIM 613179) is a rare autosomal recessive immunodeficiency. It is characterized by a progressive combined immunodeficiency (",
"    <a class=\"graphic graphic_table graphicRef64286 \" href=\"UTD.htm?14/41/15006\">",
"     table 1",
"    </a>",
"    ) and neurologic symptomatology that includes ataxia, developmental delay, and spasticity. Autoimmunity, especially autoimmune hemolytic anemia, is also frequently present.",
"   </p>",
"   <p>",
"    The disease was first described in 1975, in a patient who had absent T cell function, but intact B cell immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/1\">",
"     1",
"    </a>",
"    ]. The immunodeficiency was progressive, with normal immune functions at birth, but severe T cell deficiency with intact B cells exhibited by the age of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/2\">",
"     2",
"    </a>",
"    ]. A complete absence of PNP was noted in red blood cells, white blood cells, and fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/1\">",
"     1",
"    </a>",
"    ]. It was subsequently reported that the parents of this patient had approximately one-half of the normal levels of PNP, indicating an autosomal recessive inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic discusses the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of PNP deficiency. The related immunodeficiency, adenosine deaminase deficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=see_link\">",
"     \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link\">",
"     \"Adenosine deaminase deficiency: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNP deficiency constitutes about 1 to 2 percent of all combined immunodeficiencies. It has been reported in less than 50 patients from 30 families [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/1,4-11\">",
"     1,4-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNP deficiency is caused by mutations in the PNP gene (MIM 164050) at 14q13.1 (",
"    <a class=\"graphic graphic_figure graphicRef77023 \" href=\"UTD.htm?43/6/44137\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/7-19\">",
"     7-19",
"    </a>",
"    ]. This gene encodes the protein purine nucleoside phosphorylase (PNP), one of the enzymes involved in the purine salvage pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/20\">",
"     20",
"    </a>",
"    ]. Adenosine deaminase (ADA) deaminates adenosine to yield inosine, which is then converted to hypoxanthine by PNP. PNP also converts guanosine to guanine.",
"   </p>",
"   <p>",
"    A number of metabolites are elevated in the plasma and urine in PNP deficiency, including deoxyguanosine and deoxyinosine. There is an intracellular accumulation of their deoxy triphosphate compounds, particularly deoxyguanosine triphosphate (dGTP). The latter is toxic to T cells, a property similar to deoxyadenosine triphosphate in adenosine deaminase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=see_link\">",
"     \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear why B cells are often spared (or less severely affected) in PNP deficiency. This may be due to the selective toxicity and variability in intracellular accumulation of dGTP in different tissues. Thymocytes, because of their high apoptotic rate, generate markedly increased levels of dGTP in the thymic milieu, thereby accounting for the predominant destruction of T cells.",
"   </p>",
"   <p>",
"    PNP deficient mice exhibit impaired thymocyte differentiation, as well as a decreased number of maturing thymocytes and peripheral T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/22\">",
"     22",
"    </a>",
"    ]. The mitogenic and allogeneic response of T cells is decreased, T cell apoptosis is increased in vivo, and a higher sensitivity to irradiation is seen in vitro. An age-dependent attrition of thymocytes and impaired thymocyte differentiation is also seen in these mice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/24\">",
"     24",
"    </a>",
"    ]. From this mouse model, it was postulated that there is an inhibition of mitochondrial DNA repair due to the accumulation of dGTP in mitochondria. Similar findings were observed in a patient with PNP deficiency and dysplastic marrow morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This patient's marrow stroma and lymphocytes showed a hypersensitivity to irradiation similar to that observed in PNP deficient mice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients homozygous for PNP deficiency are symptomatic, although the onset of symptoms may be delayed for years, depending upon the mutation(s). Patients have presented at four months to six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present with frequent bacterial, viral, and opportunistic infections. Sinopulmonary infections are most common, but patients may also have liver abscesses and lymphadenitis. Patients are particularly prone to disseminated varicella and progressive vaccinia. Pulmonary tuberculosis due to disseminated BCG infection and progressive multifocal leukoencephalopathy due to polyomavirus JC (JC virus) infection have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/7,25\">",
"     7,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About two-thirds of the patients also present with progressive neurologic symptoms, including developmental delay, muscle spasticity, ataxia, and disequilibrium syndrome with pyramidal signs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/4,18,26-29\">",
"     4,18,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an increased incidence of autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/4\">",
"     4",
"    </a>",
"    ]. These include hemolytic anemia, thrombocytopenia, neutropenia, thyroiditis, systemic lupus erythematosus, cerebral vasculitis, and sclerosing cholangitis.",
"   </p>",
"   <p>",
"    Failure to thrive is reported in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. The tonsillar tissues are often absent and lymph nodes are not palpable. Some patients have splenomegaly.",
"   </p>",
"   <p>",
"    Certain malignancies, particularly lymphoma, are seen more frequently in patients with PNP deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low (below 5 percent of normal) or absent PNP activity is noted in erythrocytes, leukocytes, and fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/5,6,18\">",
"     5,6,18",
"    </a>",
"    ]. Decreased plasma levels of uric acid are also characteristic. Carriers have approximately half-normal levels of PNP.",
"   </p>",
"   <p>",
"    There is often a marked lymphopenia with low T cells (CD3+, CD4+, CD8+ cells), but normal CD19+ B cells, although patients with low number of B cells have also been reported. The delayed type hypersensitivity response is absent to a variety of antigens, such as candida, tetanus, mumps, and trichophyton. Lymphocyte proliferative responses to various mitogens and antigens may be initially normal, but decrease and become abnormal over time. Dysplastic marrow was noted in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum immunoglobulins are usually normal or elevated, with the occasional transient presence of specific antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis should be suspected in patients with recurrent infections, failure to thrive, and neurologic symptoms. Initial screening studies in such patients should include T cell enumeration, evaluation of T cell function, and serum uric acid. There are no other entities with a similar clinical presentation that have low uric acid with an associated T cell deficiency. Prenatal diagnosis is available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only curative procedure for PNP deficiency is hematopoietic stem cell transplantation, preferably with an HLA-matched or HLA-identical donor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. One child without an HLA-identical related donor successfully underwent umbilical cord blood transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients may need conditioning with immunosuppressive drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and others) prior to transplantation, because of residual immune function at early disease stages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/28\">",
"     28",
"    </a>",
"    ], although one patient was successfully transplanted without preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/32\">",
"     32",
"    </a>",
"    ]. The neurologic status may improve in some patients following successful transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/28,33\">",
"     28,33",
"    </a>",
"    ], but others may exhibit persistent developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/27\">",
"     27",
"    </a>",
"    ]. Stem cell transplants are still an option in patients who do not have an HLA-identical or HLA-matched donor, although the outcome is often unfavorable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene therapy for PNP deficiency is under investigation. Preliminary in vitro human studies and in vivo murine studies using a lentiviral vector demonstrated increased PNP expression and partial correction of some of the abnormalities associated with PNP deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the effect was transient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enzyme replacement therapy is unavailable for PNP deficiency. Thymic transplantation and transfer factor are not curative [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without successful transplantation, patients usually die within the first or second decade of life due to recurrent viral, fungal, or bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25637/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PNP deficiency is caused by mutations in the PNP gene that encodes the protein purine nucleoside phosphorylase, one of the enzymes involved in the purine salvage pathway. Defects in this enzyme lead to intracellular accumulation of toxic metabolites, particularly deoxyguanosine triphosphate (dGTP). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with frequent bacterial, viral, and opportunistic infections and failure to thrive. About two-thirds of the patients also present with progressive neurologic symptoms and one-third develop autoimmune disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low serum uric acid associated with T cell deficiency is pathognomonic for PNP deficiency. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only curative procedure for PNP deficiency is a hematopoietic stem cell transplantation. Without successful transplantation, patients usually die within the first or second decade of life due to recurrent viral, fungal, or bacterial infections. Gene therapy is under investigation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/1\">",
"      Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975; 1:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/2\">",
"      Stoop JW, Eijsvoogel VP, Zegers BJ, et al. Selective severe cellular immunodeficiency. Effect of thymus transplantation and transfer factor administration. Clin Immunol Immunopathol 1976; 6:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/3\">",
"      Snyderman R, Altman LC, Frankel A, Blaese RM. Defective mononuclear leukocyte chemotaxis: a previously unrecognized immune dysfunction. Studies in a patient with chronic mucocutaneous candidiasis. Ann Intern Med 1973; 78:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/4\">",
"      Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001.",
"    </li>",
"    <li>",
"     Osborne WRA, Ochs HD. Immunodeficiency disease due to deficiency of purine nucleoside phosphorylase. In: Primary immunodeficiency diseases: A molecular and genetic approach, Ochs HD, Smith CIE, Puck JM (Eds), Oxford University Press, Oxford 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/7\">",
"      Aytekin C, Dogu F, Tanir G, et al. Purine nucleoside phosphorylase deficiency with fatal course in two sisters. Eur J Pediatr 2010; 169:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/8\">",
"      Alangari A, Al-Harbi A, Al-Ghonaium A, et al. Purine nucleoside phosphorylase deficiency in two unrelated Saudi patients. Ann Saudi Med 2009; 29:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/9\">",
"      Parvaneh N, Teimourian S, Jacomelli G, et al. Novel mutations of NP in two patients with purine nucleoside phosphorylase deficiency. Clin Biochem 2008; 41:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/10\">",
"      Ozkinay F, Pehlivan S, Onay H, et al. Purine nucleoside phosphorylase deficiency in a patient with spastic paraplegia and recurrent infections. J Child Neurol 2007; 22:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/11\">",
"      Markert ML, Finkel BD, McLaughlin TM, et al. Mutations in purine nucleoside phosphorylase deficiency. Hum Mutat 1997; 9:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/12\">",
"      Aust MR, Andrews LG, Barrett MJ, et al. Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. Am J Hum Genet 1992; 51:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/13\">",
"      Williams SR, Gekeler V, McIvor RS, Martin DW Jr. A human purine nucleoside phosphorylase deficiency caused by a single base change. J Biol Chem 1987; 262:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/14\">",
"      Andrews LG, Markert ML. Exon skipping in purine nucleoside phosphorylase mRNA processing leading to severe immunodeficiency. J Biol Chem 1992; 267:7834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/15\">",
"      Pannicke U, Tuchschmid P, Friedrich W, et al. Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient. Hum Genet 1996; 98:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/16\">",
"      Sasaki Y, Iseki M, Yamaguchi S, et al. Direct evidence of autosomal recessive inheritance of Arg24 to termination codon in purine nucleoside phosphorylase gene in a family with a severe combined immunodeficiency patient. Hum Genet 1998; 103:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/17\">",
"      Dalal I, Grunebaum E, Cohen A, Roifman CM. Two novel mutations in a purine nucleoside phosphorylase (PNP)-deficient patient. Clin Genet 2001; 59:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/18\">",
"      Moallem HJ, Taningo G, Jiang CK, et al. Purine nucleoside phosphorylase deficiency: a new case report and identification of two novel mutations (Gly156A1a and Val217Ile), only one of which (Gly156A1a) is deleterious. Clin Immunol 2002; 105:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/19\">",
"      Grunebaum E, Zhang J, Roifman CM. Novel mutations and hot-spots in patients with purine nucleoside phosphorylase deficiency. Nucleosides Nucleotides Nucleic Acids 2004; 23:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/20\">",
"      Nyhan WL. Disorders of purine and pyrimidine metabolism. Mol Genet Metab 2005; 86:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/21\">",
"      Cohen SR, Herndon RM, McKhann GM. Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination. N Engl J Med 1976; 295:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/22\">",
"      Arpaia E, Benveniste P, Di Cristofano A, et al. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 2000; 191:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/23\">",
"      Dror Y, Grunebaum E, Hitzler J, et al. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr Res 2004; 55:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/24\">",
"      Snyder FF, Jenuth JP, Mably ER, et al. Purine nucleoside phosphorylase deficient mice exhibit both an age dependent attrition of thymocytes and impaired thymocyte differentiation. Adv Exp Med Biol 1998; 431:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/25\">",
"      Parvaneh N, Ashrafi MR, Yeganeh M, et al. Progressive multifocal leukoencephalopathy in purine nucleoside phosphorylase deficiency. Brain Dev 2007; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/26\">",
"      Tabarki B, Yacoub M, Tlili K, et al. Familial spastic paraplegia as the presenting manifestation in patients with purine nucleoside phosphorylase deficiency. J Child Neurol 2003; 18:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/27\">",
"      Baguette C, Vermylen C, Brichard B, et al. Persistent developmental delay despite successful bone marrow transplantation for purine nucleoside phosphorylase deficiency. J Pediatr Hematol Oncol 2002; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/28\">",
"      Classen CF, Schulz AS, Sigl-Kraetzig M, et al. Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone Marrow Transplant 2001; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     GeneTests www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/30626?db=genetests (Accessed on April 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/30\">",
"      Watson AR, Evans DI, Marsden HB, et al. Purine nucleoside phosphorylase deficiency associated with a fatal lymphoproliferative disorder. Arch Dis Child 1981; 56:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/31\">",
"      Myers LA, Hershfield MS, Neale WT, et al. Purine nucleoside phosphorylase deficiency (PNP-def) presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation. J Pediatr 2004; 145:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/32\">",
"      Aytekin C, Yuksek M, Dogu F, et al. An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication. Pediatr Transplant 2008; 12:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/33\">",
"      Delicou S, Kitra-Roussou V, Peristeri J, et al. Successful HLA-identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiency. Pediatr Transplant 2007; 11:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25637/abstract/34\">",
"      Liao P, Toro A, Min W, et al. Lentivirus gene therapy for purine nucleoside phosphorylase deficiency. J Gene Med 2008; 10:1282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3943 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25637=[""].join("\n");
var outline_f25_2_25637=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3943|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/6/44137\" title=\"figure 1\">",
"      Combined immunodeficiency gene defects and functional categories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/41/15006\" title=\"table 1\">",
"      Syndromes combined immunodef",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=related_link\">",
"      Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=related_link\">",
"      Adenosine deaminase deficiency: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25638="Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy";
var content_f25_2_25638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25638/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25638/contributors\">",
"     Victoria Hendrick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25638/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25638/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25638/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25638/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/2/25638/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H87621144\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For bipolar patients who plan to or do become pregnant, maintenance pharmacotherapy is often indicated to delay or prevent mood episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Onset of bipolar disorder in women typically occurs during childbearing years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/3\">",
"     3",
"    </a>",
"    ], and most patients are thus at risk for recurrences during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews indications for preconception and prenatal maintenance pharmacotherapy in female bipolar patients. Preconception and prenatal maintenance treatment, the teratogenic and postnatal risks of medications used for bipolar disorder, and contraception and preconception counseling for female bipolar patients are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=see_link\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link\">",
"       \"Bipolar disorder in women: Contraception and preconception assessment and counseling\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87620884\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIPOLAR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/4\">",
"     4",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87620142\">",
"    <span class=\"h1\">",
"     FACTORS INVOLVED IN THE DECISION TO USE MAINTENANCE PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to use preconception and prenatal maintenance pharmacotherapy involves many factors, including the [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,5-13\">",
"     1,5-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient&rsquo;s lifetime course of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Number of mood episodes",
"     </li>",
"     <li>",
"      History of episodes that included psychotic features (delusions and hallucinations)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suicide attempts",
"     </li>",
"     <li>",
"      Comorbid psychopathology (eg, anxiety or substance use disorders) and general medical illnesses",
"     </li>",
"     <li>",
"      Occupational and interpersonal functioning",
"     </li>",
"     <li>",
"      Duration of euthymia during pharmacotherapy",
"     </li>",
"     <li>",
"      Time to relapse following discontinuation of pharmacotherapy",
"     </li>",
"     <li>",
"      Time to recovery following resumption of pharmacotherapy",
"     </li>",
"     <li>",
"      Efficacy of specific medications during gravid and nongravid periods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General risk of mood episodes during pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link&amp;anchor=H1267336#H1267336\">",
"       \"Bipolar disorder in women: Contraception and preconception assessment and counseling\", section on 'Risk of maternal mood episodes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reproductive safety data for medications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Miscarriage",
"     </li>",
"     <li>",
"      Major and minor structural malformations",
"     </li>",
"     <li>",
"      Fetal growth restriction",
"     </li>",
"     <li>",
"      Neonatal toxicity and withdrawal",
"     </li>",
"     <li>",
"      Adverse postnatal developmental effects upon behavior, cognition, and emotional regulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential consequences of maternal mood episodes during pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Suicidal behavior",
"     </li>",
"     <li>",
"      Impulsive, risky behavior",
"     </li>",
"     <li>",
"      Substance abuse &nbsp;",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Poor adherence with prenatal care",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Adverse postnatal developmental effects",
"     </li>",
"     <li>",
"      Diminished mother-infant bonding",
"     </li>",
"     <li>",
"      Disrupted family functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient&rsquo;s preferences and values regarding:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recurrent mood episodes compared with teratogenicity. As an example, one patient may be more concerned about remaining asymptomatic and working to support herself and other children, while another patient with more financial resources may place more value upon avoiding fetal toxicity.",
"     </li>",
"     <li>",
"      The possibility of terminating a pregnancy if there is evidence of a malformation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Support and monitoring that is available",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87620149\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception and prenatal maintenance treatment are often indicated for female bipolar patients, based upon the high risk of recurrent mood episodes in prospective observational studies, particularly in patients who discontinued pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. However, for patients with a mild lifetime course of illness, it is reasonable to try to forego medications during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. The risk of recurrent mood episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link&amp;anchor=H1267336#H1267336\">",
"     \"Bipolar disorder in women: Contraception and preconception assessment and counseling\", section on 'Risk of maternal mood episodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87620156\">",
"    <span class=\"h2\">",
"     Mild lifetime course of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild lifetime course of illness is characterized by [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent euthymia (eg, &ge;2 years) between mood episodes",
"     </li>",
"     <li>",
"      Mood episodes that resolve completely within weeks of initiating treatment",
"     </li>",
"     <li>",
"      No history of suicide attempts or psychotic features (delusions or hallucinations)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For female bipolar patients with a mild lifetime course of illness who are planning a pregnancy, we suggest maintenance pharmacotherapy during conception and pregnancy to prevent mood episodes, based upon prospective observational studies that found untreated pregnant patients were at increased risk of recurrent mood episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/2,14\">",
"     2,14",
"    </a>",
"    ], as well as our clinical experience and that of several authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ]. However, patients with good social support may reasonably attempt to forego pharmacotherapy during the first trimester (when the risk of malformations is greatest), during the third trimester to avoid postnatal effects of drugs, or during the entire pregnancy to minimize any drug-related effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For bipolar patients who decline maintenance pharmacotherapy during the first trimester and remain euthymic, we suggest restarting pharmacotherapy during the second trimester, when organogenesis is essentially completed. A reasonable alternative is for patients to wait until they develop prodromal symptoms before resuming pharmacotherapy; however, subsyndromal symptoms are associated with an increased risk of full-blown relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For female bipolar patients who are receiving maintenance pharmacotherapy and decide to stop it in anticipation of a pregnancy, we suggest that clinicians:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Taper and discontinue pharmacotherapy over a period of two to four weeks. The risk of recurrence may be greater if medications are stopped more abruptly [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,2,19\">",
"       1,2,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link&amp;anchor=H317273#H317273\">",
"       \"Bipolar disorder in women: Contraception and preconception assessment and counseling\", section on 'Relapse after discontinuing pharmacotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Taper the medications by the same amount for each dose decrease; as an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      1200 mg per day is decreased by 300 mg per day, every five to seven days.",
"     </li>",
"     <li>",
"      Monitor patients every one to four weeks, depending upon the number and severity of mood symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Observe patients during a short medication-free trial (eg, two to three months) before patients attempt to conceive, to gauge whether patients will remain euthymic during pregnancy without medications [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/15,17\">",
"       15,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Educate patients about methods to increase their likelihood of conception (eg, home ovulation detection kits and intercourse every other day during the week ovulation is expected), to minimize the time off of medications [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bipolar symptoms recur during the medication taper, the medication is generally titrated back up to the full dose used initially to maintain euthymia. If a full-blown mood episode develops despite resuming the initial medication dose and does not improve within four to eight weeks, we suggest switching treatment. The treatment of bipolar mood episodes in patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For bipolar patients who are medication free during the entire pregnancy, we suggest restarting maintenance pharmacotherapy after delivery to prevent postpartum mood episodes, based upon the high risk of recurrent postpartum mood episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/1/5146?source=see_link&amp;anchor=H2570377#H2570377\">",
"     \"Bipolar disorder in postpartum women: Treatment\", section on 'Maintenance treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87620163\">",
"    <span class=\"h2\">",
"     Moderate to severe lifetime course of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A moderate to severe course of illness is exemplified by one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent mood episodes (eg, &ge;1 episode every two years) despite adequate maintenance treatment",
"     </li>",
"     <li>",
"      Mood episodes resistant to treatment (eg, require months to years to resolve completely)",
"     </li>",
"     <li>",
"      History of suicide attempts or psychotic features (delusions and hallucinations)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For female bipolar patients with a moderate to severe lifetime course of illness who are planning a pregnancy, we suggest preconception and prenatal maintenance pharmacotherapy to prevent mood episodes, based upon prospective observational studies that found untreated pregnant patients were at increased risk of recurrent mood episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/2,14\">",
"     2,14",
"    </a>",
"    ], as well as our clinical experience and that of several authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25638/abstract/1,15-17,20,21\">",
"     1,15-17,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87621380\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=see_link&amp;anchor=H581793#H581793\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\", section on 'Definition of bipolar disorder'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to use maintenance pharmacotherapy for female bipolar patients planning a pregnancy involves many factors, including the following. (See",
"      <a class=\"local\" href=\"#H87620142\">",
"       'Factors involved in the decision to use maintenance pharmacotherapy'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient&rsquo;s lifetime course of illness",
"     </li>",
"     <li>",
"      General risk of maternal mood episodes during pregnancy",
"     </li>",
"     <li>",
"      Reproductive safety of medications",
"     </li>",
"     <li>",
"      Potential consequences of maternal mood episodes during pregnancy",
"     </li>",
"     <li>",
"      Patient&rsquo;s preferences and values",
"     </li>",
"     <li>",
"      Support and monitoring that is available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is a highly recurrent illness, particularly in pregnant patients who forego pharmacotherapy. For patients who are planning a pregnancy, maintenance pharmacotherapy is generally indicated. However, for patients with a mild lifetime course of illness, it is reasonable to try to avoid medications during pregnancy. (See",
"      <a class=\"local\" href=\"#H87620149\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/1\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/2\">",
"      Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/3\">",
"      Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/5\">",
"      Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157:1933.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/7\">",
"      Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/8\">",
"      Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/9\">",
"      Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006; 29:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/10\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 file://www.nice.org.uk/ (Accessed on December 30, 2011).",
"    </li>",
"    <li>",
"     Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/13\">",
"      Lee HC, Lin HC. Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study. J Affect Disord 2010; 121:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/14\">",
"      Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008; 10:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/15\">",
"      Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/16\">",
"      Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/17\">",
"      Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/18\">",
"      Keller MB, Lavori PW, Kane JM, et al. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992; 49:371.",
"     </a>",
"    </li>",
"    <li>",
"     Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/20\">",
"      Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25638/abstract/21\">",
"      Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82834 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25638=[""].join("\n");
var outline_f25_2_25638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H87621380\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87621144\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87620884\">",
"      DEFINITION OF BIPOLAR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87620142\">",
"      FACTORS INVOLVED IN THE DECISION TO USE MAINTENANCE PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87620149\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87620156\">",
"      Mild lifetime course of illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87620163\">",
"      Moderate to severe lifetime course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87621380\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/82834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/82834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/1/5146?source=related_link\">",
"      Bipolar disorder in postpartum women: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25639="UIP histology";
var content_f25_2_25639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Usual interstitial pneumonia pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Patchy fibrosis with remodeling of the lung architecture shows a striking subpleural distribution. Interstitial chronic inflammation is mild with a few lymphoid aggregares. Areas of \"normal\" lung are present that lack active lesions of other interstitial lung disorders. (B) There is marked fibrosis consisting of dense collagenous scarring with remodeling of the lung architecture and cystic changes. (C) The dense collagenous scar is juxtaposed with a fibroblastic focus of loose organizing connective tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25639=[""].join("\n");
var outline_f25_2_25639=null;
var title_f25_2_25640="Late referral to nephrologists of patients with chronic kidney disease";
var content_f25_2_25640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Late referral to nephrologists of patients with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Annamaria T Kausz, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Brian JG Pereira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25640/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/2/25640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage renal disease (ESRD) experience significant morbidity, including a substantial decline in the quality of life. Mortality is also high despite improvements in the overall quality of dialysis therapy and increased health care expenditures.",
"   </p>",
"   <p>",
"    Mortality among dialysis patients is influenced by a number of factors. There is a strong association between the risk of death and age, gender, race, malnutrition, and non-renal comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition, an inadequate delivered dialysis dose, and (possibly) the use of unsubstituted cellulose and reprocessed dialysis membranes are associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=see_link\">",
"     \"Reuse of dialyzers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic kidney disease (CKD) are referred to nephrologists either early (usually for help in diagnostic and management issues) or late (usually considered late if referred shortly prior to the need for renal replacement therapy) in their clinical course. The late referral of patients with CKD may adversely affect outcomes of dialysis patients, theoretically in part due to failure to optimally manage the complications associated with kidney failure (eg, anemia, bone disease, dyslipidemia).",
"   </p>",
"   <p>",
"    Compared to those referred late, early referral may be associated with the following potential benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Informed selection of dialysis modality",
"     </li>",
"     <li>",
"      Timely placement of appropriate dialysis access",
"     </li>",
"     <li>",
"      Non-emergent initiation of dialysis",
"     </li>",
"     <li>",
"      Lower morbidity and improved rehabilitation",
"     </li>",
"     <li>",
"      Less frequent and shorter hospital stays",
"     </li>",
"     <li>",
"      Lower cost",
"     </li>",
"     <li>",
"      Improved survival",
"     </li>",
"     <li>",
"      Preemptive transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of timing of referral to the nephrologist and initiation of renal replacement therapy among patients with CKD will be reviewed here. The management of patients with CKD and indications for initiation of dialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WITHHOLDING OR NONREFERRAL FOR DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing late referral, it is helpful to first briefly review the issue of withholding of or nonreferral for dialysis of the patient with ESRD. Differences in criteria for withholding or nonreferral of patients with ESRD for renal replacement therapy may be a principal factor underlying the higher incidence rate for therapy of ESRD in the United States compared with other industrialized nations. This may be particularly true for older and sicker patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with apparent nonreferral may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physician attitudes towards offering expensive and intensive therapies to individuals of advanced age or with significant comorbid illnesses and diminished life expectancy",
"     </li>",
"     <li>",
"      Variable accuracy and completeness of ESRD reporting",
"     </li>",
"     <li>",
"      Varying availability of renal replacement therapy",
"     </li>",
"     <li>",
"      Predominant use of only certain dialysis modalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data are available on the exact proportion of patients who are not offered dialysis and the factors that influence this process. Age and comorbidity appear to strongly influence the decision to refer a patient to the nephrologist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. As an example, in a study of 2127 Brazilian patients who developed ESRD, 26 percent died without receiving dialysis, and patients over age 60 had one-twelfth the likelihood of acceptance for dialysis relative to patients 20 to 29 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey of 1020 primary care physicians (PCPs) and 549 nephrologists in the United States and Canada conducted in 1999 further illustrated this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately 20 and 15 percent of PCPs and nephrologists, respectively, reported non-referral for dialysis or withholding of dialysis, respectively, at least once during a three-year period. Patient refusal was the most common reason (60 percent), and the next most common reason was end-stage heart, lung or liver disease. This survey revealed the following additional results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      12 to 20 percent of PCPs and 4 to 9 percent of nephrologists answered there should be an age beyond which dialysis should not be offered",
"     </li>",
"     <li>",
"      About half would not offer dialysis to a patient with metastatic prostate cancer or a combative patient with uncontrolled schizophrenia",
"     </li>",
"     <li>",
"      95 to 99 percent would not offer dialysis to a patient in a persistently vegetative state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, most would offer dialysis to a younger paraplegic, ventilator dependent patient, and to an older patient who gets severe dyspnea with exertion due to chronic obstructive pulmonary disease. A greater likelihood of nonreferral of elderly and debilitated patients among primary care and other non-nephrologist physicians compared with nephrologists has been confirmed in other surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of withholding of dialysis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LATE REFERRAL TO THE NEPHROLOGIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral is considered late if the patient is referred within a few months of requiring initiation of renal replacement therapy and has not had prior adequate management of the complications of CKD. As an example, an important reason for the early identification of progressive CKD is the early institution of ACE inhibitor and other renoprotective therapy such as strict blood pressure and glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/15\">",
"     15",
"    </a>",
"    ]. The potential benefits of appropriate care were illustrated in a study of 726 patients newly referred to nephrology; the rate of decline in glomerular filtration rate (GFR) decreased substantially from 5.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 per year during the five years prior to nephrology referral to a decline of 0.35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 per year during the five years after nephrology referral [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/16\">",
"     16",
"    </a>",
"    ]. Protective therapy appears to have the greatest impact if it is initiated before the plasma creatinine concentration exceeds 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132 to 176",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or GFR is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/17\">",
"     17",
"    </a>",
"    ]. Waiting until the disease progresses further diminishes the likelihood of a successful response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most studies, referral to the nephrologist is considered late if it is within one to six months of the requirement for renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/18\">",
"     18",
"    </a>",
"    ]. Such late referrals are extremely common in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In various studies, 25 to 50 percent of patients beginning chronic renal replacement therapy in the United States required dialysis within one month of their first nephrology visit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/19,20,22\">",
"     19,20,22",
"    </a>",
"    ]; in addition, 22 to 49 percent of patients were first seen by a nephrologist less than four months prior to the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Disturbingly, some patients received no medical care at all [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar patterns relating to late referral have been reported from other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The proportion of dialysis patients who required dialysis within one month of the first visit to a nephrologist ranged from 25 percent in Paris, France [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/25\">",
"     25",
"    </a>",
"    ] to 58 percent in Sao Paulo, Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/26\">",
"     26",
"    </a>",
"    ]. The prevalence of late referral can also have significant regional variation within a country; in the larger cities of Australia, the proportion of patients referred within 3 months of needing to start dialysis ranged from 14 to 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES OF LATE REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late referral to the nephrologist can be due to unavoidable causes, the referral biases of physicians, patient factors, socioeconomic status of the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the structure of the health care system(s) within a certain country [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Unavoidable causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unavoidable causes of late referral include ESRD that follows acute kidney injury, \"asymptomatic\" kidney failure only presenting at an advanced stage, or patient's refusal to seek help until symptoms occur.",
"   </p>",
"   <p>",
"    Patients may resist referral to a nephrologist for a variety of reasons, including patient denial regarding the presence of kidney failure, lack of appropriate understanding of their condition, fear of dialysis procedures, fear of cost, distance from treatment center, or the desire to remain with the local physician. The frequency of unavoidable late referral ranges from 12 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/23,25,31,32\">",
"     23,25,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Referral biases of physicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clear differences among physicians in the rate of referral of patients with CKD to a nephrologist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/33\">",
"     33",
"    </a>",
"    ]. Several factors might influence nephrology referral decisions by physicians, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of training about guidelines regarding timing or indications for referral [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poor communication between referring physicians and specialists, which has been implicated as a factor that adversely affects the quality and cost of patient care [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/20,34-36\">",
"       20,34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Economic factors, including fear of losing patients, and the loss of income from office visits, hospitalizations, or tests. In addition, nephrologists may subsequently refer patients to other specialists for non-renal issues that can be handled by primary physicians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Structure of the health care system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most developing countries, patients have limited access to medical care, commonly resulting in the need for emergency dialysis upon presentation to the nephrologist. Unfortunately, this type of presentation is also common in developed countries such as the United States, where many patients have no direct, insured access to medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The structural and economic constraints imposed upon referring physicians by health care organizations may also dictate the frequency and timing of referral to the nephrologist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United Kingdom and Canada, and within certain health plans in the United States, a patient may be seen by a nephrologist only after referral from a primary care physician. Referrals from such physicians may be limited by some of the factors previously mentioned.",
"     </li>",
"     <li>",
"      Pressure to contain costs by avoiding subspecialty referral is a policy promoted by some health maintenance organizations (HMOs) in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequently, certain payers have developed disease management organizations, which offer a continuum of care beginning with diseases that cause kidney failure through the requirement for renal replacement therapy, and have placed the nephrologist at the center of the patient care team [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/38\">",
"     38",
"    </a>",
"    ]. This development could potentially reverse earlier trends and channel patients to the nephrologist in larger numbers and in a more timely manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Socioeconomic patient characteristics are also associated with late referral in some studies. This was illustrated in a review of 460 patients starting dialysis over a four-year period, of whom 46, 37 and 17 percent presented &lt;1 month, 1 to 3 months, and &gt;3 months prior to initiating dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/30\">",
"     30",
"    </a>",
"    ]. Those presenting at &lt;1 month were more likely to be alcoholic (34 percent), substance abusers (37 percent), and homeless or unemployed (28 percent), compared to 10 percent or fewer among those presenting at &gt;3 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF LATE REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and economic consequences of late referral to the nephrologist have mostly been described from uncontrolled or retrospective studies. Comparison of study results is further hindered by differences in definition of early and late referral, and duration of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metabolic and hematologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients referred late to the nephrologist invariably present with biochemical indices of severe uremia and an imminent need for dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/22-26,39\">",
"     22-26,39",
"    </a>",
"    ]. In most studies addressing this, compared to patients referred early, patients referred late also have a significantly greater degree of acidosis, anemia, hypocalcemia, hypoalbuminemia, and hyperphosphatemia.",
"   </p>",
"   <p>",
"    As an example, in a study examining the predialysis care of 135 patients with CKD, compared to early referral, those referred late (referred less than four months before the initiation of dialysis) had a higher incidence of hypoalbuminemia (80 versus 56 percent) and a hematocrit of less than 28 percent (55 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advanced metabolic abnormalities at the time of initiation of dialysis reflect suboptimal care of progressive CKD; this possibly contributes to the high morbidity and costs of initiation of dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hospitalization and cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delayed referral of patients with CKD is associated with a greater likelihood of prolonged hospitalization around the time of initiation of dialysis as well as with higher costs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This was best shown in a 2007 meta-analysis of eight studies consisting of 3220 patients in which number of days in hospital was significantly higher for late versus early referral patients (25 versus 14 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late referral patients are also hospitalized more frequently for the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/20,24,25,31,40,42,43\">",
"     20,24,25,31,40,42,43",
"    </a>",
"    ]. These adverse associations are probably due in part to a greater prevalence of uremic complications and other serious illnesses, such as uncontrolled hypertension and pulmonary edema. In addition, vascular access placement and the management of complications related to this aspect of dialysis care are a frequent cause of hospitalization and a large component of the cost of care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/19,44,45\">",
"     19,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the pressure to control health care costs by avoiding hospitalization, a large proportion of patients with ESRD in the United States are hospitalized for initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/24,46\">",
"     24,46",
"    </a>",
"    ]. This may in part be due to late referral, but perceptions of nephrologists that dialysis should be initiated in the hospital setting, as well as regional regulations requiring a first dialysis to be at an inpatient facility, may also have contributed. Multidisciplinary patient education and follow-up programs may decrease the likelihood of hospitalization for initiation of dialysis, and lower the frequency of emergency initiation and time spent in hospital during the first month of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Selection of dialysis modality, emergent first dialysis and permanent access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early referral to the nephrologist enables discussion of the preferred mode of renal replacement therapy to suit the patients' lifestyle and timely placement of a permanent dialysis access. An informed decision on dialysis modality made under non-emergency circumstances reduces the likelihood of a subsequent change in dialysis modality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/22,31\">",
"     22,31",
"    </a>",
"    ]. Furthermore, patients referred late are less likely to receive a kidney transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients referred to the nephrologist in a timely manner tend to have a functioning permanent access at the start of dialysis compared to only a small minority of late referrals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/23,24,26,27,31,48-50\">",
"     23,24,26,27,31,48-50",
"    </a>",
"    ]. One study evaluated the clinical characteristics of 139 patients who, prior to the initiation of dialysis, received medical care provided by a nephrologist or a generalist, or no medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared to the group cared for by generalists, patients treated by nephrologists were significantly less likely to have required a temporary venous catheter for the first dialysis (36 versus 89 percent). The late referral of patients has therefore resulted in a large number of dialysis patients without permanent vascular access at the time of initiation of dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late referrals may also affect the choice of chronic hemodialysis access. Although primary arteriovenous (AV) fistulas are the preferred form of vascular access, polytetrafluoroethylene (PTFE) grafts are utilized in almost three times as many patients as are endogenous fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/51\">",
"     51",
"    </a>",
"    ]. Since fistulas require a much longer time to mature than do PTFE grafts, the placement of grafts may be favored by nephrologists for those patients referred late who require immediate dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since a primary AV fistula requires months to mature and is the access of choice, patients should be referred for surgery to attempt access construction when it is estimated that the patient is within one year of the anticipated need for dialysis as manifested by a GFR less than 25",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    a plasma creatinine concentration greater than 4",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (354",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    or a rapid rate of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Loss of kidney function and rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, late referral to a nephrologist may not permit the timely institution of therapy aimed at decreasing the rate of loss of kidney function. Timely referral also permits the enrollment of patients into a multidisciplinary program that addresses the physical, logistic, social, emotional and vocational problems encountered during life on dialysis. Participation in such predialysis educational programs has been associated with higher employment rates and delay in the need for initiation of renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of studies have examined the association between timing of nephrology referral and deaths subsequent to initiation of dialysis, particularly during the first year of dialysis. To best assess this association, a 2007 meta-analysis evaluated this correlation among 20 studies that included over 12,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/40\">",
"     40",
"    </a>",
"    ]. Compared with early referral, late referral was associated with a significantly increased risk of all-cause mortality (risk ratio of 1.99, 95% CI 1.66-2.39) and one-year mortality (RR of 2.08, 95% CI 1.31-3.31). However, significant heterogeneity was noted. Similar findings were noted in subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/41,55,56\">",
"     41,55,56",
"    </a>",
"    ], and did not seem to vary with the cause of kidney disease (diabetic versus nondiabetic kidney disease) or whether patients were elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/56\">",
"     56",
"    </a>",
"    ]. The positive impact of nephrology care on mortality was confirmed in a retrospective cohort study of 39,031 patients in the Department of Veteran's Health Affairs system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients with multiple nephrology visits during the year had a substantially lower mortality compared with patients who were not seen by a nephrologist or seen only once by a nephrologist, with adjusted hazard ratios 0.80, 0.68 and 0.40 for two, three and four nephrology visits.",
"   </p>",
"   <p>",
"    Studies relating to mortality may suffer from lead-time bias. In general, such bias may be observed with early diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early initiation of treatment of a condition, resulting in the patient being expected to live longer from the time of diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    initiation of treatment.",
"   </p>",
"   <p>",
"    Future studies relating to the timing of initiation of dialysis may consider the effect of lead-time bias by adjusting for the estimated duration of time the patient would have remained off dialysis, which could be predicted using an estimated rate of decline of kidney function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMPACT OF NEPHROLOGY CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigorously conducted prospective randomized trials to determine the impact of referral to a nephrologist are not available. However, a prospective, nonrandomized study suggested some benefit. In this study, 52 patients with diabetic nephropathy in one health care facility were referred to see a nephrologist every six months, and their status was compared to 65 patients in another health care facility who were not referred, but continued routine care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/58\">",
"     58",
"    </a>",
"    ]. Baseline characteristics were similar, and GFR and blood pressure were 84 and 79",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, and",
"    <span class=\"nowrap\">",
"     140/76",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     140/79",
"    </span>",
"    mmHg, in the referred and control groups, respectively. After 12 months of observation, among patients referred to nephrology, blood pressure control was better",
"    <span class=\"nowrap\">",
"     (130/70",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     145/77",
"    </span>",
"    in the control group), and there was a slightly lesser decline in GFR (-3.4 versus -12",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 in the control group). Patients in the referred group were more likely to be started on an ACE inhibitor (or ARB) and statins, and to have NSAIDS discontinued. Other elements of care, such as smoking cessation and glycemic control, were not different in the two groups.",
"   </p>",
"   <p>",
"    The results of this study must be interpreted with caution, since it is not a randomized trial and patients in the control group had slightly worse kidney function at baseline. However, it does suggest greater implementation of strategies to slow progression by nephrologists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     KDOQI CLINICAL PRACTICE GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the suggested guidelines issued by the National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    regarding the timing of referral of CKD patients to a nephrologist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25640/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newly diagnosed patients should be referred for initial evaluation of cause of kidney failure and for recommendation of therapies to reverse the kidney failure or slow progression.",
"     </li>",
"     <li>",
"      Patients with established CKD should be referred for recommendations regarding management of complications of kidney failure when the GFR falls below 60",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Patients should be referred for education and planning for renal replacement therapy and close co-management of complications when the GFR falls below 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The late referral of patients with chronic kidney disease (CKD) may adversely affect outcomes of dialysis patients due to failure to optimally manage associated complications such as anemia, bone disease and dyslipidemia. Referral is considered late if the patient is referred within a few months of requiring initiation of renal replacement therapy and has not had prior adequate management of the complications of CKD. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Late referral to the nephrologist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential benefits of early referral include: informed selection of dialysis modality; timely placement of appropriate dialysis access and non-emergent initiation of dialysis; lower morbidity and improved rehabilitation; less frequent and shorter hospital stays; lower cost; improved survival; and preemptive transplant. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late referrals are common in the United States and in other parts of the world. Approximately 25 to 50 percent of patients beginning chronic renal replacement therapy in the United States require dialysis within one month of their first nephrology visit. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Late referral to the nephrologist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasons for late referral to a nephrologist include unavoidable factors such as ESRD following acute kidney injury or asymptomatic kidney failure that presents at an advanced stage. Denial, lack of understanding or fear among patients may contribute to delayed evaluation by a nephrologist. Decreased awareness of indications for referral or fear of loss of income among physicians may also contribute. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes of late referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasons for nonreferral for dialysis include: physician attitudes towards offering expensive and intensive therapies to individuals with diminished life expectancy; variable accuracy and completeness of ESRD reporting; varying availability of renal replacement therapy; and predominant use of only certain dialysis modalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Withholding or nonreferral for dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The consequences of late referral include increased likelihood of severe uremia, a greater degree of acidosis, anemia, hypocalcemia, hypoalbuminemia, and hyperphosphatemia. Delayed referral is generally associated with a greater likelihood of prolonged hospitalization around the time of initiation of dialysis and higher costs. The majority of patients referred early to the nephrologist are more likely to have a fistula in place, rather than a less preferred graft or catheter. Mortality is increased among patients who are referred late. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Consequences of late referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newly diagnosed patients should be referred to a nephrologist for evaluation of cause of kidney failure and for recommendation of therapies to reverse the kidney failure or slow progression. The extent of continued nephrology co-management should take into consideration the severity of renal function impairment and associated complications, and rate of progression. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'KDOQI clinical practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with established CKD who are not routinely seen by a nephrologist should be referred when complications of kidney failure develop, which is typically when the estimated GFR falls below 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2, for recommendations regarding appropriate management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'KDOQI clinical practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKD patients should be referred to a nephrologist when the estimated GFR falls below 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2, for education and planning for renal replacement therapy and close co-management of complications. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'KDOQI clinical practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/1\">",
"      US Renal Data System. USRDS 2008 Annual Data Report. Am J Kidney Dis 2009; 1(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/2\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/3\">",
"      Keane WF, Collins AJ. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 1994; 24:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/4\">",
"      Port FK. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/5\">",
"      Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/6\">",
"      Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/7\">",
"      Feldman HI, Kinosian M, Bilker WB, et al. Effect of dialyzer reuse on survival of patients treated with hemodialysis. JAMA 1996; 276:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/8\">",
"      Khan IH, Catto GR, Edward N, MacLeod AM. Chronic renal failure: factors influencing nephrology referral. QJM 1994; 87:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/9\">",
"      Sesso R, Fernandes PF, An&ccedil;&atilde;o M, et al. Acceptance for chronic dialysis treatment: insufficient and unequal. Nephrol Dial Transplant 1996; 11:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/10\">",
"      Challah S, Wing AJ, Bauer R, et al. Negative selection of patients for dialysis and transplantation in the United Kingdom. Br Med J (Clin Res Ed) 1984; 288:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/11\">",
"      Mendelssohn DC, Kua BT, Singer PA. Referral for dialysis in Ontario. Arch Intern Med 1995; 155:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/12\">",
"      Parry RG, Crowe A, Stevens JM, et al. Referral of elderly patients with severe renal failure: questionnaire survey of physicians. BMJ 1996; 313:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/13\">",
"      Sekkarie M, Cosma M, Mendelssohn D. Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States. Am J Kidney Dis 2001; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/14\">",
"      Visser A, Dijkstra GJ, Huisman RM, et al. Differences between physicians in the likelihood of referral and acceptance of elderly patients for dialysis-influence of age and comorbidity. Nephrol Dial Transplant 2007; 22:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/15\">",
"      Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/16\">",
"      Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 2006; 21:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/17\">",
"      Ghossein C, Serrano A, Rammohan M, Batlle D. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience. Semin Nephrol 2002; 22:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/18\">",
"      Eadington DW. Delayed referral for dialysis. Nephrol Dial Transplant 1996; 11:2124.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System. USRDS 1997 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/20\">",
"      Campbell, JD, Ewigman, B, Hosokawa, M, Van Stone, JC. The timing of referral of patients with end-stage renal disease. Nephrol Dial Transplant 1989; 18:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/21\">",
"      Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 1994; 121:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/22\">",
"      Schmidt RJ, Domico JR, Sorkin MI, Hobbs G. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 1998; 32:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/23\">",
"      Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999; 10:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/24\">",
"      Ifudu O, Dawood M, Homel P, Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 1996; 28:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/25\">",
"      Jungers P, Zingraff J, Albouze G, et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993; 8:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/26\">",
"      Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant 1996; 11:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/27\">",
"      Lorenzo V, Martn M, Rufino M, et al. Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients: an observational cohort study. Am J Kidney Dis 2004; 43:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/28\">",
"      Cass A, Cunningham J, Snelling P, et al. Urban disadvantage and delayed nephrology referral in Australia. Health Place 2003; 9:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/29\">",
"      Wauters JP, Lameire N, Davison A, Ritz E. Why patients with progressing kidney disease are referred late to the nephrologist: on causes and proposals for improvement. Nephrol Dial Transplant 2005; 20:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/30\">",
"      Obialo CI, Ofili EO, Quarshie A, Martin PC. Ultralate referral and presentation for renal replacement therapy: socioeconomic implications. Am J Kidney Dis 2005; 46:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/31\">",
"      Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis. Br Med J (Clin Res Ed) 1984; 288:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/32\">",
"      Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant 1992; 7:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/33\">",
"      Boulware LE, Troll MU, Jaar BG, et al. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis 2006; 48:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/34\">",
"      Cummins RO, Smith RW, Inui TS. Communication failure in primary care. Failure of consultants to provide follow-up information. JAMA 1980; 243:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/35\">",
"      Lee T, Pappius EM, Goldman L. Impact of inter-physician communication on the effectiveness of medical consultations. Am J Med 1983; 74:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/36\">",
"      Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. BMC Nephrol 2008; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/37\">",
"      Garella S. The costs of dialysis in the USA. Nephrol Dial Transplant 1997; 12 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/38\">",
"      Bahr, T, Burke, M, Carey, N, Coplon, N, et al. Integrated renal disease management: A provider's response to capitation and an evolving managed care marketplace. Dialysis &amp; Transplantation 1997; 26:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/39\">",
"      Jungers P, Zingraff J, Page B, et al. Detrimental effects of late referral in patients with chronic renal failure: a case-control study. Kidney Int Suppl 1993; 41:S170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/40\">",
"      Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007; 120:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/41\">",
"      Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 2011; 124:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/42\">",
"      Levin A, Lewis M, Mortiboy P, et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 1997; 29:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/43\">",
"      Arora P, Kausz AT, Obrador GT, et al. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol 2000; 11:740.",
"     </a>",
"    </li>",
"    <li>",
"     Lowrie, EL. Internal record. National Medical Care 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/45\">",
"      Feldman HI, Held PJ, Hutchinson JT, et al. Hemodialysis vascular access morbidity in the United States. Kidney Int 1993; 43:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/46\">",
"      Hood SA, Schillo B, Beane GE, et al. An analysis of the adequacy of preparation for end-stage renal disease care in Michigan. Michigan Renal Plan Task Force. ASAIO J 1995; 41:M422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/47\">",
"      Cass A, Cunningham J, Snelling P, Ayanian JZ. Late referral to a nephrologist reduces access to renal transplantation. Am J Kidney Dis 2003; 42:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/48\">",
"      Arce CM, Mitani AA, Goldstein BA, Winkelmayer WC. Hispanic ethnicity and vascular access use in patients initiating hemodialysis in the United States. Clin J Am Soc Nephrol 2012; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     Muirhead, N, Blyndal, K. Potential cost savings of planned dialysis start. J Am Soc Nephrol 1995 (Abstract); 6:553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/50\">",
"      Lee T, Barker J, Allon M. Associations with predialysis vascular access management. Am J Kidney Dis 2004; 43:1008.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System. USRDS 1996 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/52\">",
"      Chertow GM. Grafts vs fistulas for hemodialysis patients: equal access for all? JAMA 1996; 276:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/53\">",
"      NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/54\">",
"      Rasgon S, Schwankovsky L, James-Rogers A, et al. An intervention for employment maintenance among blue-collar workers with end-stage renal disease. Am J Kidney Dis 1993; 22:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/55\">",
"      Hasegawa T, Bragg-Gresham JL, Yamazaki S, et al. Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol 2009; 4:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/56\">",
"      de Jager DJ, Voormolen N, Krediet RT, et al. Association between time of referral and survival in the first year of dialysis in diabetics and the elderly. Nephrol Dial Transplant 2011; 26:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/57\">",
"      Tseng CL, Kern EF, Miller DR, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008; 168:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/58\">",
"      Mart&iacute;nez-Ram&iacute;rez HR, Jalomo-Mart&iacute;nez B, Cort&eacute;s-Sanabria L, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis 2006; 47:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25640/abstract/59\">",
"      NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39:S65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7212 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-C3EBFED581-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25640=[""].join("\n");
var outline_f25_2_25640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WITHHOLDING OR NONREFERRAL FOR DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LATE REFERRAL TO THE NEPHROLOGIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES OF LATE REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Unavoidable causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Referral biases of physicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Structure of the health care system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONSEQUENCES OF LATE REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metabolic and hematologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hospitalization and cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Selection of dialysis modality, emergent first dialysis and permanent access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Loss of kidney function and rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMPACT OF NEPHROLOGY CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      KDOQI CLINICAL PRACTICE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7096?source=related_link\">",
"      Reuse of dialyzers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25641="Nutritional considerations in type 1 diabetes mellitus";
var content_f25_2_25641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional considerations in type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Linda M Delahanty, MS, RD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25641/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25641/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/2/25641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet and physical activity are critically important in the treatment of type 1 diabetes. Basic principles of nutritional management, however, are often poorly understood, by both clinicians and their patients.",
"   </p>",
"   <p>",
"    The nutrition prescription for patients with type 1 diabetes should aim to optimally manage the \"ABCs\" of diabetes control:",
"    <strong>",
"     A",
"    </strong>",
"    1C,",
"    <strong>",
"     b",
"    </strong>",
"    lood pressure and LDL-",
"    <strong>",
"     c",
"    </strong>",
"    holesterol. The prescription must also be tailored for the individual patient to address diabetes complications and other concomitant conditions. The nutritional goals for people with type 1 diabetes are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain as near-normal blood glucose levels as possible, by integrating insulin therapy into each individual's diet and physical activity patterns.",
"     </li>",
"     <li>",
"      Achieve optimal blood pressure and lipid levels.",
"     </li>",
"     <li>",
"      Provide adequate calories for achieving and maintaining a reasonable body weight, normal growth, and development.",
"     </li>",
"     <li>",
"      Manage risk factors and prevent complications of diabetes, both acute (hypoglycemia and short-term illness) and long-term (hypertension, hyperlipidemia, renal disease, cardiovascular disease, and other micro- and macrovascular complications).",
"     </li>",
"     <li>",
"      Improve overall health through healthful food choices.",
"     </li>",
"     <li>",
"      Address individual nutrition needs, incorporating personal and cultural preferences, willingness to change, and maintaining the pleasure of eating by restricting choice only when clearly appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative importance of each nutritional goal varies with individual patient characteristics.",
"   </p>",
"   <p>",
"    The role of nutrition and the development of a medical nutrition therapy plan for a patient with type 1 diabetes are discussed here. Nutrition for patients with type 2 diabetes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .) The effects of exercise on patients with diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .) Insulin management for type 1 diabetes is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .) An overview of management of children and adolescents with type 1 diabetes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL NUTRITION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical nutrition therapy (MNT) is the process by which the nutrition prescription is tailored for people with diabetes based on medical, lifestyle, and personal factors and is an integral component of diabetes management and diabetes self-management education [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized controlled trials of MNT have demonstrated decreases in A1C of approximately 1 percent in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In the Diabetes Control and Complications Trial (DCCT), specific diet behaviors were associated with achieving up to a 1 point lower mean A1C (8 versus 7 percent) in the intensive treatment group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adherence to the negotiated meal plan (diet consistency)",
"     </li>",
"     <li>",
"      Adjusting food",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin in response to hyperglycemia",
"     </li>",
"     <li>",
"      Adjusting insulin dose for meal size and content",
"     </li>",
"     <li>",
"      Appropriate treatment of hypoglycemia (not overtreating hypoglycemia)",
"     </li>",
"     <li>",
"      Consistent habits with regard to consumption of a bedtime snack and avoidance of extra nighttime snacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proper attention to diet is a major factor in minimizing hypoglycemia and weight gain while achieving glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Glycemic control has been shown to markedly diminish the likelihood of neuropathy, nephropathy, retinopathy, and coronary artery disease (CAD) in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MNT for type 1 diabetes should consider five key aspects:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consistency in day-to-day carbohydrate intake at meals and snacks",
"     </li>",
"     <li>",
"      Adjusting insulin for variations in blood glucose, food, or activity",
"     </li>",
"     <li>",
"      Weight management (caloric intake balanced with caloric expenditure)",
"     </li>",
"     <li>",
"      Nutritional content (balance of selected protein, carbohydrates, and fats)",
"     </li>",
"     <li>",
"      Meal-insulin timing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARBOHYDRATE CONSISTENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations in food intake, particularly carbohydrate intake, can result in erratic blood sugars and hypoglycemia in patients with type 1 diabetes. Intensive insulin regimens, which combine a basal insulin with short-acting premeal insulins, do allow for some flexibility in the carbohydrate content of meals. In one study of patients receiving intensive insulin therapy, as an example, the total amount of carbohydrate in the meal did not influence glycemic response if premeal insulin was adjusted for variations in the carbohydrate content of the meal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients who use short-acting insulin analogs or who use insulin pumps may need to take additional bolus insulin injections with snacks that contain more than 10 to 15 g of carbohydrate.",
"   </p>",
"   <p>",
"    For patients receiving fixed doses of short- and intermediate-acting insulin, however, day-to-day consistency in the amount of carbohydrate and source of carbohydrate at meals and snacks is more important. Carbohydrate consistency for these patients has been associated with lower A1C levels, whereas day-to-day variations in calorie, protein, or fat intakes were not significantly related to A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Meal planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several meal planning approaches to achieve carbohydrate consistency, including basic and advanced carbohydrate counting, the exchange system, and sample menus. The best approach for individual patients is determined by an assessment of their lifestyle and learning capabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Basic carbohydrate counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In its simplest form, the goal of carbohydrate counting is to promote glycemic control by implementing a consistent pattern of carbohydrate consumption with meals and snacks day-to-day. Since carbohydrate intake directly determines postprandial blood sugar, management of carbohydrate consumption and appropriate insulin adjustments for identified quantities of carbohydrate can improve glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have been instructed in carbohydrate counting consume a predetermined total amount of carbohydrate at meals and snacks each day, calculated in grams of carbohydrate per food portion. The calculated carbohydrate intake is derived from an optimal percentage of total calories from carbohydrates, based on nutrition goals and the usual eating pattern.",
"   </p>",
"   <p>",
"    Patients need to be comfortable with simple arithmetical computations. Most patients will require specific training in carbohydrate counting, usually by a dietitian, to set appropriate meal and snack targets and learn to measure or estimate portion sizes and read food labels (",
"    <a class=\"graphic graphic_table graphicRef51729 \" href=\"UTD.htm?42/27/43451\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Exchange system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exchange system was developed in 1950 by the American Dietetic Association, the American Diabetes Association, and the US Public Health Service as an educational tool to provide consistency in meal planning and allow a wider variety of food choices for people with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/13\">",
"     13",
"    </a>",
"    ]. Originally, the exchange lists categorized foods into six groups:",
"    <span class=\"nowrap\">",
"     starch/bread,",
"    </span>",
"    meat and meat substitutes, vegetables, fruit, milk, and fat. Each portion of food listed within a group was \"exchangeable\" because it contained approximately the same nutritional value in terms of calories, carbohydrate, protein, and fat.",
"   </p>",
"   <p>",
"    The food groups have been more recently categorized into three groups, to simplify the teaching of carbohydrate consistency concepts. These three groups are carbohydrate, meat and meat substitutes, and fat (",
"    <a class=\"graphic graphic_table graphicRef52063 \" href=\"UTD.htm?25/18/25900\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75559 \" href=\"UTD.htm?24/52/25421\">",
"     table 3",
"    </a>",
"    ). The exchange lists also identify foods that are good sources of fiber, and foods that have a high sodium content [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exchange system meal planning approach can be used as a tool to help patients achieve calorie, fat, and carbohydrate goals. However, many patients find that it is a complicated system to learn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sample menus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sample menus are defined meal menus that specify the time and amounts of food to be eaten at each meal and snack. For patients with type 1 diabetes, menus are developed to meet calorie needs and provide consistent carbohydrate intake at meals and snacks. Dietitians typically tailor the menus to incorporate food preferences and medical nutrition therapy goals. Sample menus are created after review of a person's typical food intake; they are best suited for patients who have fairly routine eating habits and who do not eat a wide variety of foods. They also are appropriate for patients who need structured guidance on what to eat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Insulin adjustments",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Advanced carbohydrate counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a more advanced level, carbohydrate counting focuses on adjustment of food, insulin, and activity based on patterns from detailed logs. The patient needs to record time of meals and snacks, the amount and type of food eaten, amount of carbohydrate consumed, insulin dose, physical activity, and blood glucose results. Patients should first practice eating consistent amounts of carbohydrate at meals and snacks so that baseline insulin requirements can be matched to usual carbohydrate intake using pre- and postprandial blood glucose testing results. When pre- and postprandial blood glucose levels are in the target range, then insulin-to-carbohydrate ratios can be determined as follows:",
"   </p>",
"   <p>",
"    Divide the number of grams of carbohydrate eaten at the meal by the number of units of pre-meal insulin (eg, 45 g carbohydrate divided by 3 units of insulin is a 1 to 15 ratio). Insulin to carbohydrate ratios can vary with time of day, and are affected by stress, illness, and variations in physical activity.",
"   </p>",
"   <p>",
"    Two other methods to calculate insulin-to-carbohydrate ratios are the 450 to 500 rule and the weight method [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/13\">",
"     13",
"    </a>",
"    ]. These methods do not take into account individual variation and therefore are not as accurate as using detailed records.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      450 to 500 rule &mdash; Calculate the insulin-to-carbohydrate ratio as follows:",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       Regular insulin",
"      </a>",
"      -to-carbohydrate ratio = 450 divided by total daily dose (TDD) of insulin.",
"      <br/>",
"      <br/>",
"      Rapid acting insulin-to-carbohydrate ratio = 500 divided by TDD of insulin.",
"      <br/>",
"      <br/>",
"      As an example, if the TDD is 50 units and the patient uses a regimen with rapid-acting insulin, then the insulin-to-carbohydrate ratio would be 500 divided by 50 or 1 unit for 10 g carbohydrate.",
"     </li>",
"     <li>",
"      Weight method &mdash; The weight method uses the data in the table (",
"      <a class=\"graphic graphic_table graphicRef52751 \" href=\"UTD.htm?9/38/9835\">",
"       table 4",
"      </a>",
"      ) to calculate the carbohydrate to insulin ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Elevated blood glucose levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;An insulin correction factor can be used to adjust insulin dose for hyperglycemia before meals or between meals. To calculate the insulin correction factor:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      , divide 1500 by TDD",
"     </li>",
"     <li>",
"      For rapid-acting insulin, divide 1800 by TDD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, if a patient using rapid-acting insulin has a TDD of 45 units, then the insulin correction factor would be 1 unit for every 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    reduction in blood sugar (1800 divided by 45). If the patient had a premeal blood sugar of 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and wanted to correct to a premeal blood glucose of 100",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    then the patient would take an extra 2 units of rapid-acting insulin to correct to the target of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and add the number of units needed to cover the carbohydrates consumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient were hypoglycemic (blood glucose &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    then the patient would treat the hypoglycemia with 10 to 15 g of fast-acting carbohydrate for glucose levels of 51 to 70",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and with 20 to 30 g of fast-acting carbohydrate for blood glucose levels &le;50",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Retest 15 minutes after ingestion and repeat treatment as needed based on blood sugar levels. Once blood glucose is &gt;70",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the patient should use the appropriate insulin dose to cover carbohydrate intake at the meal.",
"   </p>",
"   <p>",
"    If the meal following the hypoglycemic episode is going to be delayed, a snack containing another 15 grams of carbohydrate should be consumed. A pattern of overtreating hypoglycemia can result in a greater than desired rise in blood glucose and increased calorie intake, resulting in weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY/EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is a significant component of diabetes management. Benefits of exercise include improved glycemic control, weight control, reduction in co-morbidities (hypertension, dyslipidemia, and cardiovascular disease), improved mood, and quality of life. The Institute of Medicine recommends that most adults engage in 30 minutes or more of moderate intensity physical activity on most days of the week [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/14\">",
"     14",
"    </a>",
"    ]. Individuals for whom weight loss and weight maintenance are a concern may need more than this, and 60 to 90 minutes of moderate to vigorous intensity activity is encouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although exercise has not been consistently shown to improve glycemic control for patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], patients who learn to self-adjust their diet or insulin to accommodate exercise can achieve near-normal A1C levels without undue hypoglycemia. For patients who are trying to lose weight, it is preferable to adjust insulin doses rather than increase food intake to compensate for exercise. Timing of exercise in relation to insulin dose, type, mode of delivery, and time of injection should be considered. Patients with diabetes should check blood sugar levels before and after exercising, especially in the beginning of an exercise program, to evaluate glycemic response to exercise and adjust insulin regimen. Patients should be advised to have a snack handy, in case blood sugar levels drop too low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WEIGHT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative importance of caloric intake for an individual patient is dependent on several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Current weight in relationship to desirable and healthy body weight",
"     </li>",
"     <li>",
"      Weight history",
"     </li>",
"     <li>",
"      Fat distribution and waist circumference",
"     </li>",
"     <li>",
"      Muscle mass",
"     </li>",
"     <li>",
"      Genetics",
"     </li>",
"     <li>",
"      A1C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lowering caloric intake and inducing weight loss are of major importance for overweight (Body Mass Index [BMI] &ge;25 to 29.9) and obese (BMI &ge;30) patients with type 1 diabetes, since the risk of comorbidities associated with excess adipose tissue increases with BMI in these ranges. If patients have been close to ideal weight for several years and have a near normal A1C, then their current caloric intake is most likely appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Weight gain with intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain is a potential adverse effect of intensive diabetes therapy in type 1 diabetes, and occurs when insulin dosing matches nutritional intake and glycosuria is eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The mean increase in weight in patients in the DCCT study was 5.1 kg in the intensive therapy group and 2.4 kg in the conventional therapy group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/18\">",
"     18",
"    </a>",
"    ]. At study end, 33 percent of the intensive therapy group was overweight compared with 19 percent of the conventional treatment group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If A1C is high enough to promote glycosuria, then lowering calorie intake by an additional 250 to 300 calories per day is necessary to prevent weight gain with intensification of diabetes therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/5\">",
"     5",
"    </a>",
"    ]. Other strategies to minimize weight gain with intensive therapy are to reduce insulin doses preferentially for patterns of hypoglycemia rather than increasing meal size or adding an undesired snack. To reduce calories further, it is helpful to reduce fat intake and try to keep carbohydrate intake consistent to minimize risk of hypoglycemia.",
"   </p>",
"   <p>",
"    Weight gain is most prominent in women, especially those with high A1C values at baseline, and has been a cause of noncompliance with insulin therapy. As examples, approximately 30 percent of women with type 1 diabetes in one study occasionally omitted insulin injections intentionally [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/20\">",
"     20",
"    </a>",
"    ]; in a second study, 9 percent did so on a regular basis in order to avoid weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Eating disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Estimating desirable body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desirable body weight range can be roughly estimated by adding and subtracting 10 percent to the weights calculated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women over 5 feet (152 cm):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      100 lb (45 kg) plus 5 lb (2.3 kg) for each additional inch (2.5 cm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women under 5 feet (152 cm):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      100 lb (45 kg) minus 5 lb (2.3 kg) for each additional inch (2.5 cm) under five feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men over 5 feet (152 cm):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      106 lb (48 kg) plus 6 lb (2.7 kg) for each additional inch (2.5 cm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Body Mass Index (BMI) is now commonly used in research and clinical care as a classification of weight status and is calculated as: [weight in Kg &nbsp;&divide; &nbsp;(height in m)2]. Optimal body weight is a BMI between 18.5 and 24.9 (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Estimating caloric intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several formulas are available to estimate baseline caloric intake for weight maintenance. A commonly used formula considers the patient's age, sex, height, weight, and usual level of physical activity (",
"    <a class=\"graphic graphic_table graphicRef66100 \" href=\"UTD.htm?27/9/27803\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rough estimate of caloric needs to maintain body weight can be determined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Men, active women &mdash; 15",
"      <span class=\"nowrap\">",
"       kcal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Most women, sedentary men, and adults over 55 years &mdash; 13",
"      <span class=\"nowrap\">",
"       kcal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Sedentary women, obese adults &mdash; 10",
"      <span class=\"nowrap\">",
"       kcal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Pregnant, lactating women &mdash; 15 to 17",
"      <span class=\"nowrap\">",
"       kcal/lb",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To estimate caloric needs for weight loss of one to two pounds per week, subtract 500 to 1000 calories from weight maintenance calories. It is important that low calorie diets (less than 1200",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    are not adopted without review to be sure nutritional needs are met. Very low calorie diets (less than 800",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    require medical supervision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NUTRITIONAL CONTENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal macronutrient composition of the diet for patients with diabetes is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/25\">",
"     25",
"    </a>",
"    ]. The best mix of carbohydrate, protein, and fat may vary depending on the individual. ADA nutritional guidelines do not give specific total dietary compositional targets, except for the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either low carbohydrate (ie, less than the Recommended Dietary Allowance or RDA of 130 g per day) or low fat calorie-restricted diets are effective for short-term (up to one year) weight loss. However, the long-term safety and durability of very low carbohydrate diets are unknown. In addition, excessive elimination of carbohydrates reduces important nutrient intake and diet palatability.",
"     </li>",
"     <li>",
"      Saturated fat should be less than 7 percent of calories and there should be minimal trans fat.",
"     </li>",
"     <li>",
"      Total cholesterol should be less than 200 mg daily.",
"     </li>",
"     <li>",
"      Usual dietary protein of 15 to 20 percent of calories is appropriate in diabetes in the absence of significant renal insufficiency. Reduction of protein intake to 0.8 to 1.0",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      body weight per day in diabetic individuals with early states of chronic kidney disease (CKD), and to 0.8",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      body weight per day in later stages of CKD may improve measures of renal function. High protein diets (&gt;20 percent of calories) are not recommended for weight loss as the long-term effects on kidney function are unknown.",
"     </li>",
"     <li>",
"      Fiber intake should be at least 14 grams per 1000 calories daily; higher fiber intake may improve glycemic control.",
"     </li>",
"     <li>",
"      A reduced sodium intake of 1500 mg per day, with a diet high in fruits, vegetables, and low fat dairy products, is prudent.",
"     </li>",
"     <li>",
"      Sugar, alcohols, and non-nutritive sweeteners are safe when consumed within daily levels established by the FDA. When calculating carbohydrate content of foods, one-half of the sugar alcohol content should be counted in the total carbohydrate content of the food.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is universally agreed that managing carbohydrate content is central to glycemic control. Excess total fat might increase the already high risk of atherosclerosis, and excess protein could promote the development of diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controversy exists whether distinguishing between types of carbohydrate (ie, refined or whole grain, mono- or disaccharides) is important, or if only the total amount of carbohydrate is significant. ADA recommendations advise that one-half the grain content consumed be whole grain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/26\">",
"     26",
"    </a>",
"    ]. Intake of sucrose does not need to be restricted, although care should be taken to avoid excess calories; sucrose can be substituted for other carbohydrate sources in the meal plan or, if added, covered with insulin. Use of added fructose as a sweetener is not recommended, as it may adversely affect lipids, but there is no need to avoid fructose occurring naturally in fruits and vegetables.",
"   </p>",
"   <p>",
"    The relative importance of other dietary factors is also uncertain; these include protein, types of fat, fiber (especially soluble), acid content of foods, particle size, food processing regimens, and rate and efficiency of digestion and absorption of different nutrients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. People with type 1 diabetes typically consume more saturated fat than is recommended. Among intensively treated patients with type 1 diabetes in the DCCT, saturated fat intake was close to 13 percent of calories during the trial and diets higher in total and saturated fat and lower in carbohydrate were associated with worse glycemic control independent of exercise and BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glycemic index and glycemic load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foods containing the same amount of carbohydrate can have significantly different glycemic effects. These differences led to the development of the concepts of glycemic index and glycemic load:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glycemic index is an in vivo measure of the relative impact of carbohydrate-containing foods on blood glucose. A particular food's glycemic index is determined by evaluating the incremental rise in blood glucose after ingestion of a portion of the test food containing 50 g of carbohydrate, compared with the same amount of carbohydrate from a reference food, which is usually white bread or glucose [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Some examples of low-glycemic index foods include non-starchy vegetables, nuts, legumes, and certain grains such as barley and converted rice. High glycemic index foods include potatoes, candies, white bread, and other refined products made from grains (",
"      <a class=\"graphic graphic_table graphicRef71978 \" href=\"UTD.htm?8/40/8845\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Glycemic load is the product of the glycemic index value of a food and its total carbohydrate content [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The concept of the glycemic load was developed because the blood glucose response is influenced not only by the quality of the carbohydrate consumed (ie, the glycemic index), but also by the quantity of carbohydrate consumed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The glycemic index and glycemic load may have far greater health implications than glycemic control alone. Several prospective studies have associated diets high in glycemic index and glycemic load with an increased risk of developing type 2 diabetes, coronary heart disease, and some cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ]. Data also suggest that low-glycemic load diets are particularly effective among the most susceptible individuals, those who are already overweight and insulin resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/34\">",
"     34",
"    </a>",
"    ]. In a meta-analysis of 14 randomized trials in patients with type 1 and type 2 diabetes mellitus, low-glycemic index diets resulted in a reduction in A1C of 0.43 percent (95% CI 0.13-0.72), compared with a standard ADA diet that had a high glycemic index [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/36\">",
"     36",
"    </a>",
"    ]. In a cross-sectional study of patients with type 1 diabetes (n = 2810) from 31 clinics throughout Europe, the dietary glycemic index independently and positively correlated with A1C level [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/35\">",
"     35",
"    </a>",
"    ]. A more detailed discussion of these effects can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"     \"Dietary carbohydrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The glycemic index and glycemic load can be difficult to understand and implement for most patients, although many patients in research studies have been taught to average their intake to a glycemic index of less than 55 (referenced to glucose = 100). Information is lacking from food labels and other sources, and mixing foods in a recipe further complicates calculations.",
"   </p>",
"   <p>",
"    The ADA recommends carbohydrate counting as the best means of glycemic control, while encouraging intake of whole grains and fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/1\">",
"     1",
"    </a>",
"    ]. It is possible this will change as information on the glycemic index becomes more widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate amounts of alcohol, when ingested with food, do not significantly increase plasma glucose or serum insulin; the carbohydrate content of the non-alcohol component of a mixed drink may raise blood glucose, however [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/26\">",
"     26",
"    </a>",
"    ]. If patients choose to ingest alcohol, they should limit their intake to no more than one drink per day for women or two drinks per day for men; alcohol should be consumed with food. Patients with type 1 diabetes should use blood glucose monitoring to assess any immediate or delayed effects of alcohol intake on blood glucose levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of these observations, we recommend customizing dietary recommendations to the patients' abilities and lifestyle, with changes centered on managing total carbohydrate intake at meals and snacks, and use of whole grains in preference to refined grains and starches.",
"   </p>",
"   <p>",
"    Carbohydrate counting, as recommended by the ADA, is the most common meal planning approach for patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/7\">",
"     7",
"    </a>",
"    ]. For patients with the ability to take additional steps to manage diabetes and prevent complications, learning to adjust insulin doses for variations in food intake or changes in activity will be beneficial.",
"   </p>",
"   <p>",
"    It is also crucial to distinguish between types of fat in the diet, lowering saturated and avoiding hydrogenated fats, while consistently including monounsaturated and omega-3 fatty acids in the diet [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/26\">",
"     26",
"    </a>",
"    ]. Protein intake should be appropriate to medical condition. In addition, patients with diabetes also need to assure that their diet is adequate in fiber content, and essential vitamins and minerals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MEAL-INSULIN TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, consistent timing of food intake was an important aspect of nutrition in patients treated with insulin regimens to attain goals for glycemic control without undue hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/4,12,37\">",
"     4,12,37",
"    </a>",
"    ]. Meal timing at regular intervals is most important for patients receiving fixed doses of short- and intermediate-acting insulin. Newer rapidly-acting insulin preparations, however, allow for more flexibility in meal schedules and content.",
"   </p>",
"   <p>",
"    Traditional insulin regimens were based on the injection of roughly the same amount of insulin at the same time each day. If the amount and timing of carbohydrate intake varied widely, blood glucose profiles fluctuated, with little chance of achieving target A1C values without a substantial risk of hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H2#H2\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Lack of control due to diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative approach for patients receiving intensive insulin therapy is to determine how much short- or rapid-acting insulin is needed to cover a certain amount of carbohydrate. Patients vary considerably in the amount of insulin required to cover a set amount of carbohydrate; some patients need a different carbohydrate-to-insulin ratio at different meals. Once the ratio is established, patients have flexibility to vary the amount of carbohydrate ingested at particular meals.",
"   </p>",
"   <p>",
"    As an example, a patient may have been told to eat 60 grams of carbohydrate with their evening meal and precede this with 4 units of rapid-acting insulin. This means that they are using 1 unit to cover every 15 grams, and can decrease their insulin dose proportionately if they plan to eat less carbohydrate at a meal. Facility with carbohydrate counting strategies becomes essential in making these adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EATING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eating disorders are relatively common in patients with diabetes, especially in female adolescents and young adults with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/38\">",
"     38",
"    </a>",
"    ]. Eating disorders have a deleterious impact on glycemic control and on long-term outcome in these patients. One study evaluated 91 females with type 1 diabetes (mean age 15 years) at baseline and at follow-up four to five years later [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/39\">",
"     39",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-six (29 percent) had a self-reported eating disorder at baseline, which persisted in 16 (18 percent) at follow-up.",
"     </li>",
"     <li>",
"      Among the patients with normal eating patterns at baseline, 15 percent had disordered eating at follow-up.",
"     </li>",
"     <li>",
"      Dieting or omission of insulin for weight loss and binge eating were the most common eating disorders.",
"     </li>",
"     <li>",
"      Disordered eating was associated with adverse outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. At baseline, A1C values were significantly higher in those with highly disordered eating than in those with moderately disordered or normal eating (11.1 versus 8.9 and 8.7 percent, respectively). Patients with eating disorders were more likely to have retinopathy at follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to evaluate patients with diabetes, especially young women, for an eating disorder (or misreporting of insulin administration) and arrange appropriate psychological and nutritional counseling and support when indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROMOTING DIETARY COMPLIANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While nutritional counseling by clinicians in the diabetes healthcare team is essential, ultimately the patient determines what he or she is willing or able to do to achieve improved glycemic control.",
"   </p>",
"   <p>",
"    The dietary prescription should begin by determining the patient's dietary preferences, physical activity patterns, medication dosing and adherence, social support, education level, time constraints, and other challenges. A dietary history, along with several days of food records, is helpful in an assessment of caloric intake, dietary content, and carbohydrate consistency. Recognizing that this is not always possible in the context of the clinician visit, a brief 24-hour recall will usually provide an assessment that will serve as a basis for initial changes, and can be improved upon at follow-up visits.",
"   </p>",
"   <p>",
"    Once sufficient data are obtained, changes can be advised to move the patient toward a more ideal diet and eating pattern. It is important to remember that the more marked the changes are from what the patient likes to eat, the less likely that the patient will adhere with the dietary prescription [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/12\">",
"     12",
"    </a>",
"    ]. The patient's own food records and motivation to learn can be helpful in guiding decisions for meal planning approaches; choices between a detailed exchange system, sample menus, basic or more advanced carbohydrate counting approaches, or a low-glycemic index diet can be made on an individual basis based on an assessment of lifestyle and learning capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diet consistent in carbohydrate is desired in patients with type 1 diabetes interested in intensive insulin therapy. The patient about to begin intensive insulin therapy must be cautioned about the potential to gain weight, and the need for weight monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motivating a patient to make a long-term commitment to dietary alterations is a challenge. Achieving and maintaining weight reduction is difficult in any obese patient. Compliance can occasionally be enhanced by the rapid and often dramatic improvements in glycemic control.",
"   </p>",
"   <p>",
"    Teaching is best done in a setting where real food can be used, so that the patient can become familiar with household measures and can improve his or her ability to estimate the carbohydrate content of foods commonly eaten. This is often best accomplished in dietary workshops for small groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During follow-up visits, it is important for the clinician to ask specifically about diet and exercise to reinforce their importance. Ideally, a patient should be able to quote his or her nutrition and exercise prescription in detail. Patients with type 1 diabetes will also need to be able to specify how many grams of carbohydrate they aim to eat at each meal and snack during the day. Most patients should also be able to specify their insulin correction factor and carbohydrate-to-insulin ratios for meals. Patients should be well-trained in methods to treat hypoglycemia to prevent over-compensation.",
"   </p>",
"   <p>",
"    Many patient factors influence the likelihood of successful dietary intervention. The following observations have been made concerning the likelihood of inducing and maintaining weight loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise can increase the degree of weight loss, and the likelihood that it will be maintained. In one study of 74 patients, as an example, the patients who maintained weight loss were more likely to exercise (90 versus 34 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"       \"Effects of exercise in diabetes mellitus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Self-monitoring for weight and dietary intake, in conjunction with goal setting and individualized problem-solving, can be helpful in achieving and maintaining weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/44\">",
"       44",
"      </a>",
"      ]. Patients who were more successful with weight loss were conscious of their eating behaviors (70 versus 30 percent), used available social supports (70 versus 38 percent), and confronted problems directly (90 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who refuse food when offered by others, and are able to stop eating when appropriate, are more likely to maintain weight loss and achieve glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Providing structured meal plans and grocery lists is very effective, but no additional benefit appears to be obtained by providing the actual food (even if free) or giving financial incentives to lose weight [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25641/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Periodic adjustments are necessary in the patient's comprehensive plan for diet, exercise, stress, and pharmacological interventions to achieve and maintain glycemic control and prevent complications. The clinician needs to maintain awareness of the patient's changing lifestyle patterns, and help the patient make adaptations in their plan accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"       \"Patient information: Diabetes and diet (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=see_link\">",
"       \"Patient information: Counting carbs if you do not use insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       \"Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=see_link\">",
"       \"Patient information: Carb counting and your child&rsquo;s diet (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"       \"Patient information: Managing diabetes in school (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=see_link\">",
"       \"Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five key aspects of the nutritional management of type 1 diabetes are (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical nutrition therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Consistency in day-to-day carbohydrate intake",
"     </li>",
"     <li>",
"      Adjusting insulin for variations in blood glucose, food or activity",
"     </li>",
"     <li>",
"      Weight management",
"     </li>",
"     <li>",
"      Nutritional content",
"     </li>",
"     <li>",
"      Meal-insulin timing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintaining a consistent day-to-day carbohydrate intake at meals and snacks allows insulin adjustments to be made to usual carbohydrate intake. Learning to adjust insulin in response to hyperglycemia and variations in carbohydrate intake at meals is a more advanced skill. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carbohydrate consistency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modifying caloric intake is important for the overweight patient with type 1 diabetes or the patient with a high A1C and glycosuria who is about to intensify diabetes management. Approximate caloric intake and estimates of desirable body weight can be made by formulas presented above. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Estimating caloric intake'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Estimating desirable body weight'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ADA recommends restricting saturated fats to &lt;7 percent of dietary calories, minimizing trans fats, increasing fiber, and avoiding high protein diets. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nutritional content'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eating disorders are common among young female patients with type 1 diabetes, manifested most commonly as bulimia and weight loss due to purposely missed or reduced insulin doses; poor glycemic control and increased retinopathy are consequences. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Eating disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Promoting dietary compliance is a challenge, and a registered dietitian can be helpful in developing and monitoring a nutrition prescription. Compliance can be fostered by tailoring the nutrition prescription to the individual patient's preferences and lifestyle, reviewing food diaries, and providing positive feedback with improved glycemic control. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Promoting dietary compliance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/1\">",
"      Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/2\">",
"      Kulkarni K, Castle G, Gregory R, et al. Nutrition Practice Guidelines for Type 1 Diabetes Mellitus positively affect dietitian practices and patient outcomes. The Diabetes Care and Education Dietetic Practice Group. J Am Diet Assoc 1998; 98:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/3\">",
"      Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/4\">",
"      Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care 1993; 16:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/5\">",
"      Delahanty L, Simkins SW, Camelon K. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. The DCCT Research Group. J Am Diet Assoc 1993; 93:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/6\">",
"      Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/7\">",
"      Anderson EJ, Richardson M, Castle G, et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993; 93:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/8\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/9\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/10\">",
"      Rabasa-Lhoret R, Garon J, Langelier H, et al. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care 1999; 22:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/11\">",
"      Wolever TM, Hamad S, Chiasson JL, et al. Day-to-day consistency in amount and source of carbohydrate intake associated with improved blood glucose control in type 1 diabetes. J Am Coll Nutr 1999; 18:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/12\">",
"      Nuttall FQ. Carbohydrate and dietary management of individuals with insulin-requiring diabetes. Diabetes Care 1993; 16:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Pastors JG, Waslaski J, Gunderson H. Diabetes meal-planning strategies. In: Diabetes Medical Nutrition Therapy and Education, Ross TA, Boucher JL, O'Connell BS (Eds), American Diabetes Association, Chicago, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/14\">",
"      Brooks GA, Butte NF, Rand WM, et al. Chronicle of the Institute of Medicine physical activity recommendation: how a physical activity recommendation came to be among dietary recommendations. Am J Clin Nutr 2004; 79:921S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/15\">",
"      American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004; 27 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     Wasserman DH, Davis SN, Zinman B. Fuel metabolism during exercise in health and diabetes. In: Handbook of Exercise in Diabetes, Ruderman N, Devlin JT, Schneider SH, Kriska A (Eds), American Diabetes Association, Alexandria, VA 2002. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/17\">",
"      Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc) 2005; 41:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/18\">",
"      Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/19\">",
"      Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995; 18:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/20\">",
"      Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/21\">",
"      Biggs MM, Basco MR, Patterson G, Raskin P. Insulin withholding for weight control in women with diabetes. Diabetes Care 1994; 17:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/22\">",
"      Close EJ, Wiles PG, Lockton JA, et al. The degree of day-to-day variation in food intake in diabetic patients. Diabet Med 1993; 10:514.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, The National Academies Press, Washington, DC 2002.",
"    </li>",
"    <li>",
"     Escott-Stump S. Nutrition and Diagnosis-Related Care, 5th, Lippincott Williams &amp; Wilkins, Hagerstown, MD 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/25\">",
"      Franz MJ. Carbohydrate and diabetes: is the source or the amount of more importance? Curr Diab Rep 2001; 1:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/26\">",
"      American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/27\">",
"      Wolever TM. Carbohydrate and the regulation of blood glucose and metabolism. Nutr Rev 2003; 61:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/28\">",
"      Johnston CS, Buller AJ. Vinegar and peanut products as complementary foods to reduce postprandial glycemia. J Am Diet Assoc 2005; 105:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/29\">",
"      Delahanty LM, Nathan DM, Lachin JM, et al. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 2009; 89:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/30\">",
"      Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/31\">",
"      Wolever TM, Nguyen PM, Chiasson JL, et al. Determinants of diet glycemic index calculated retrospectively from diet records of 342 individuals with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1994; 59:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/32\">",
"      Liu, S. Insulin resistance, hyperglycemia and risk of major chronic diseases: a dietary perspective. Proceedings of the Nutrition Society of Australia 1998; 22:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/33\">",
"      Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000; 71:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/34\">",
"      Dumesnil JG, Turgeon J, Tremblay A, et al. Effect of a low-glycaemic index--low-fat--high protein diet on the atherogenic metabolic risk profile of abdominally obese men. Br J Nutr 2001; 86:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/35\">",
"      Buyken AE, Toeller M, Heitkamp G, et al. Glycemic index in the diet of European outpatients with type 1 diabetes: relations to glycated hemoglobin and serum lipids. Am J Clin Nutr 2001; 73:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/36\">",
"      Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/37\">",
"      Franz MJ. Finding the right fit for meal planning. Diabetes Care 1993; 16:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/38\">",
"      Mannucci E, Rotella F, Ricca V, et al. Eating disorders in patients with type 1 diabetes: a meta-analysis. J Endocrinol Invest 2005; 28:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/39\">",
"      Rydall AC, Rodin GM, Olmsted MP, et al. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med 1997; 336:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/40\">",
"      Peveler RC, Bryden KS, Neil HA, et al. The relationship of disordered eating habits and attitudes to clinical outcomes in young adult females with type 1 diabetes. Diabetes Care 2005; 28:84.",
"     </a>",
"    </li>",
"    <li>",
"     Green JA. Meal planning approaches for nutritional management of diabetes. In: Handbook of Diabetes Nutritional Management, Powers MA (Ed), Aspen Pub, Rockville, MD 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/42\">",
"      Heller SR, Clarke P, Daly H, et al. Group education for obese patients with type 2 diabetes: greater success at less cost. Diabet Med 1988; 5:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/43\">",
"      Kayman S, Bruvold W, Stern JS. Maintenance and relapse after weight loss in women: behavioral aspects. Am J Clin Nutr 1990; 52:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/44\">",
"      Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005; 82:230S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/45\">",
"      Guare JC, Wing RR, Marcus MD, et al. Analysis of changes in eating behavior and weight loss in type II diabetic patients. Which behaviors to change. Diabetes Care 1989; 12:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/46\">",
"      Jeffery RW, Wing RR, Thorson C, et al. Strengthening behavioral interventions for weight loss: a randomized trial of food provision and monetary incentives. J Consult Clin Psychol 1993; 61:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25641/abstract/47\">",
"      Wing RR, Jeffery RW, Burton LR, et al. Food provision vs structured meal plans in the behavioral treatment of obesity. Int J Obes Relat Metab Disord 1996; 20:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1765 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25641=[""].join("\n");
var outline_f25_2_25641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL NUTRITION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARBOHYDRATE CONSISTENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Meal planning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Basic carbohydrate counting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Exchange system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sample menus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Insulin adjustments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Advanced carbohydrate counting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Elevated blood glucose levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHYSICAL ACTIVITY/EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WEIGHT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Weight gain with intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Estimating desirable body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Estimating caloric intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NUTRITIONAL CONTENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glycemic index and glycemic load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MEAL-INSULIN TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EATING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROMOTING DIETARY COMPLIANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/27/43451\" title=\"table 1\">",
"      Carb counting getting started",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/18/25900\" title=\"table 2\">",
"      Exchange lists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/52/25421\" title=\"table 3\">",
"      Sample exchange system menu",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/38/9835\" title=\"table 4\">",
"      Insulin to carb ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/9/27803\" title=\"table 5\">",
"      Estimating calories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/40/8845\" title=\"table 6\">",
"      Glycemic index and load values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=related_link\">",
"      Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/52/37699?source=related_link\">",
"      Patient information: Carb counting and your child&rsquo;s diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=related_link\">",
"      Patient information: Counting carbs if you do not use insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/20/3397?source=related_link\">",
"      Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25642="Hepatotoxicity due to herbal medications and dietary supplements";
var content_f25_2_25642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatotoxicity due to herbal medications and dietary supplements",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Anne M Larson, MD, FACP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/2/25642/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/2/25642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medical (CAM) therapies are a diverse group of practices which includes the use of herbal and dietary supplements (HDS) (",
"    <a class=\"graphic graphic_table graphicRef72867 \" href=\"UTD.htm?19/31/19963\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"     1",
"    </a>",
"    ]. The use of CAM therapies in the United States increased dramatically since 1990. As many as 65 percent of the population reported the use of CAM therapies, depending upon how they were defined, with out-of-pocket costs in 2005 exceeding $27 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The most commonly used CAM therapies are herbal and dietary supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 1997 and 2002, overall CAM therapy use remained relatively stable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"     1",
"    </a>",
"    ]. By contrast, the use of HDS increased by 50 percent (from 23 million adult users to over 38 million) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"     1",
"    </a>",
"    ]. The estimated cost of HDS alone in 2008 was $4.8 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, about 95 percent of CAM users were self-medicating (compared to 85 percent in 1997) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"     1",
"    </a>",
"    ]. Women and non-Hispanic whites were more likely to use CAM therapies, with greater use in persons younger than 65 years of age and in those with a higher annual household income [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1,2,7,8\">",
"     1,2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of herbal preparations can be traced back as far as ancient Egypt, China, India, and Sumeria, and formulations have been expanded upon over the centuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Many patients consider \"natural\" herbal remedies to be completely free of unwanted side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This is concerning since many herbal products have biological activity that can lead to severe toxicity or that interact with each other or prescription medications. Fewer than 40 percent of patients disclose to their clinician that they are using these products [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/1,2,14\">",
"     1,2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235294330\">",
"    <span class=\"h1\">",
"     DATABASE OF DRUGS, HERBS, AND SUPPLEMENTS ASSOCIATED WITH HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"     searchable database",
"    </a>",
"    of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1962, the Kefauver-Harris Drug Amendment was introduced, which required that all over-the-counter and prescription products show proof of safety and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/16\">",
"     16",
"    </a>",
"    ]. CAMS were assigned to the food supplement category and had a lower threshold of required evidence for safety [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/16\">",
"     16",
"    </a>",
"    ]. An attempt by the Food and Drug Administration (FDA) in the early 1990s to develop more strict regulations was met with significant opposition by supplement manufacturers, lobbyists, and consumers.",
"   </p>",
"   <p>",
"    The Dietary Supplement Health and Education Act (DSHEA) of 1994 was an amendment to the US Federal Food, Drug and Cosmetic Act (FD&amp;C) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17\">",
"     17",
"    </a>",
"    ]. The DSHEA defined dietary supplements as products that are taken by mouth and intended to supplement the diet, including vitamins, minerals, amino acids, and herbal or botanical remedies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/9,17-19\">",
"     9,17-19",
"    </a>",
"    ]. These products may be in the form of tablets, capsules, soft gels, gel caps, liquids, teas, or powders. The DSHEA named the USP-National Formulary as its official reference for herbal preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17\">",
"     17",
"    </a>",
"    ]. The United States Pharmacopeia (USP) is an official public standards-setting authority for all prescription and over-the-counter medicines and other health care products manufactured or sold in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/20\">",
"     20",
"    </a>",
"    ]. The USP also sets standards for food ingredients and dietary supplements.",
"   </p>",
"   <p>",
"    Under the DSHEA, the FDA is responsible for proving whether or not there are safety concerns and taking action against any unsafe dietary supplement product only after it reaches the market. Products that were already in distribution prior to 1994 were allowed to remain on the market; their use is often justified based upon experience from trial and error, not rigorous scientific scrutiny. Supplement manufacturers are not required to register themselves or their product with the FDA prior to distribution or obtain FDA approval before producing or selling supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. The FDA monitors product information, such as labeling and claims, and also monitors safety through a voluntary dietary supplement adverse event reporting system. Manufacturers are not required to advise the FDA of adverse events. The Federal Trade Commission regulates advertising of dietary supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DSHEA requires that manufacturers establish product safety before marketing. Manufacturers must also ensure that the product label is truthful and not misleading. The label must contain a complete list all ingredients contained in the product and the identity of the manufacturer. Manufacturers must also limit the claims that can be made (health claims, nutrient content claims, and",
"    <span class=\"nowrap\">",
"     structure/function",
"    </span>",
"    claims) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Structure/function",
"    </span>",
"    claims are those which claim that the nutrient or dietary ingredient is intended to affect normal structure or function in humans (ie, \"calcium builds strong bones\"). They may also describe the means by which a nutrient or dietary ingredient acts to maintain such",
"    <span class=\"nowrap\">",
"     structure/function",
"    </span>",
"    (ie, \"fiber maintains bowel regularity\"), or they may describe general well-being from consumption of the nutrient or dietary ingredient.",
"    <span class=\"nowrap\">",
"     Structure/function",
"    </span>",
"    claims may also express a benefit related to a nutrient deficiency disease (ie, \"vitamin C prevents scurvy\"). In this last setting, they must include a statement telling how widespread the disease is in the United States.",
"   </p>",
"   <p>",
"    If a manufacturer makes a",
"    <span class=\"nowrap\">",
"     structure/function",
"    </span>",
"    claim on the supplement label, the DSHEA requires a disclaimer: \"This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.\"",
"   </p>",
"   <p>",
"    The Final Rule for Current Good Manufacturing Practices for Dietary Supplements was passed in 2007 as a further step in attempting to ensure the safety of HDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/23\">",
"     23",
"    </a>",
"    ]. This rule requires that manufacturers follow certain standards in the production of HDS. Manufacturers are required to verify the contents of the product (ie, identify the ingredients, strength), and ensure that the product is contamination free. However, the Final Rule does not address the safety or efficacy of the product ingredient itself.",
"   </p>",
"   <p>",
"    The widespread use of mixed remedies and the lack of randomized, placebo-controlled clinical trials make any review of the safety and efficacy of herbal remedies troublesome. In addition, conformity to the USP standards is voluntary.",
"   </p>",
"   <p>",
"    There may be significant discrepancies between the ingredients listed on the label and the actual contents of the preparation. This is especially true of preparations containing multiple plants or herbs (ie, Chinese remedies), which may be adulterated either unintentionally or intentionally by cheaper, more toxic herbs, heavy metals, microbials, and Western medicines (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or steroids) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,12,24-38\">",
"     11,12,24-38",
"    </a>",
"    ]. As many as one-third or more of products can be adulterated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/28\">",
"     28",
"    </a>",
"    ]. There can also be variations between batches of the same herbal product from the same manufacturer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/24,39\">",
"     24,39",
"    </a>",
"    ]. It can be difficult to identify the agent actually responsible for the hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FREQUENCY OF HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no precise estimates of the frequency of hepatotoxicity attributable to HDS. Patients often do not report the use of herbal products to their clinicians, and self-medicate with large amounts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/2,36\">",
"     2,36",
"    </a>",
"    ]. As a result, hepatotoxicity associated with herbal use may be missed. The United States Drug-Induced Liver Injury Network (DILIN) found that about 10 percent of cases of drug-induced liver injury (DILI) could be attributed to HDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/41\">",
"     41",
"    </a>",
"    ]. Others have implicated HDS in up to 68 percent of cases of DILI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17,42,43\">",
"     17,42,43",
"    </a>",
"    ]. Additionally, it has been estimated that fewer than 1 percent of adverse reactions to dietary supplements are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are often reluctant to discuss use of",
"    <span class=\"nowrap\">",
"     HDS/CAMs",
"    </span>",
"    or do not recognize them as \"medications\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/36\">",
"     36",
"    </a>",
"    ]. It is important for the clinician to discuss the use of these products with the patient in a nonjudgmental manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .) Patients can then be educated on the potential adverse effects and drug-herb interactions that may occur. This may prevent the development of hepatotoxicity. However, the unreported use of herbal remedies must be considered as a possible etiology in any setting of clinical manifestations of liver injury. Liver injury may present as asymptomatic liver enzyme elevations, jaundice, hepatitis (nausea, vomiting, abdominal pain), acute liver failure with coagulopathy and encephalopathy, or with signs and symptoms of cirrhosis. Frequently, non-specific constitutional symptoms occur.",
"   </p>",
"   <p>",
"    Continued use of the offending product greatly increases morbidity once hepatotoxicity has developed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/25,44\">",
"     25,44",
"    </a>",
"    ]. The patient may even increase the use of the herbal preparation to help \"treat\" the new symptoms. As in other cases of elevated liver enzymes, all other causes of liver disease must be ruled out. Patients often use herbal remedies and concoctions to treat their chronic disease and may, in fact, exacerbate it [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/3-5,39\">",
"     3-5,39",
"    </a>",
"    ]. Continued ingestion of the herbal preparation in the face of ongoing hepatotoxicity may lead to cirrhosis or acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/12,45\">",
"     12,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern of liver injury is similar to that seen with other forms of drug-induced liver injury. It can be hepatocellular, cholestatic, a mixture of the two, or vascular (ie, sinusoidal obstruction syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .) The diagnosis of liver injury secondary to HDS can be difficult. The relationship between the exposure and the hepatic toxicity is not always clear. In addition, patients may be taking multiple preparations, making identification of a single offending agent impossible. They may also have concomitant liver disease (such as alcoholism or hepatitis C virus infection), which can produce similar clinical and laboratory features. There are no specific tests or markers to confirm a diagnosis of drug-induced liver injury from either a manufactured medication or an herbal remedy. Proving that an HDS causes liver injury relies on both chronological and clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Council for International Organizations of Medical Sciences (CIOMS) developed a series of standard designations of drug-induced liver disorders and classification of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/48\">",
"     48",
"    </a>",
"    ]. The United States FDA Drug Hepatotoxicity Steering Committee proposed modifications to the CIOMS classification scheme for classifying hepatotoxicity in clinical trials (",
"    <a class=\"graphic graphic_table graphicRef76892 \" href=\"UTD.htm?3/32/3595\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These guidelines are used as markers of hepatotoxicity in clinical trials.",
"   </p>",
"   <p>",
"    Several scoring systems have been proposed to standardize such assessment, the best known of which include: the RUCAM (Roussel Uclaf Causality Assessment Method) scale, more recently called the CIOMS (Council for International Organizations of Medical Sciences) scale, the Maria and Victorino scale, and a simpler clinical diagnostic scale (CDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/47,51-53\">",
"     47,51-53",
"    </a>",
"    ]. Studies that have compared these models suggest that the RUCAM (CIOMS) scale may have better discriminative ability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/46,54\">",
"     46,54",
"    </a>",
"    ]. While these scales have not been validated in the setting of herbal medications, they may be useful (",
"    <a class=\"graphic graphic_table graphicRef55524 \" href=\"UTD.htm?23/23/23934\">",
"     table 3",
"    </a>",
"    ). None of these scales address all risk factors in all patients, and none are used routinely in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/47\">",
"     47",
"    </a>",
"    ]. One of the most important diagnostic criteria remains the exclusion of other causes of liver injury. RUCAM (CIOMS) has been validated independently in the setting of rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features suggesting drug toxicity include lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after beginning the drug, and improvement after the product is withdrawn. If an immunologic reaction is suspected, the illness will generally recur upon reintroduction of the offending substance. While it remains the gold standard for the diagnosis of drug-induced liver injury, rechallenge is not advised. Nonspecific symptoms developing after introduction of a drug (such as nausea, anorexia, malaise, fatigue, right upper quadrant pain, or pruritus) may indicate drug toxicity and should prompt evaluation.",
"   </p>",
"   <p>",
"    Key elements for attributing liver injury to an HDS are similar to those for other drug products and include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure must precede the onset of liver injury (although the latent period is highly variable)",
"     </li>",
"     <li>",
"      Underlying liver disease should be sought and ruled out",
"     </li>",
"     <li>",
"      Injury may improve when the drug is stopped (although in some cases injury may initially worsen for days or weeks, while in fulminant cases, declining liver biochemical tests may indicate deterioration rather than improvement)",
"     </li>",
"     <li>",
"      Liver injury may have recurred more rapidly and severely after repeated exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of therapy for herbal hepatotoxicity is withdrawal of the offending toxin. Early recognition of toxicity is important to permit assessment of severity and monitoring for acute liver failure. Corticosteroids are of unproven benefit for most forms of drug hepatotoxicity, although they may have a role for treating patients with hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients should be followed by serial biochemical measurements. Hepatology consultation may be warranted.",
"   </p>",
"   <p>",
"    Recovery should be expected in the majority of patients after discontinuing the drug. More advanced disease requires supportive therapy, with acute liver failure often leading to death or need for liver transplantation. The development of jaundice following introduction of a drug potentially portends a poor prognosis and should also prompt immediate referral to a center with expertise in hepatology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECIFIC HEPATOTOXIC HERBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The many descriptions in the literature of the toxic effects of herbal remedies underscore the view that not all natural products are harmless. Hepatotoxicity may be the most frequent adverse reaction to herbal remedies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Some of the more frequently reported offending herbs include Chinese remedies and teas (Jin Bu Huan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], Ma-Huang [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]), germander [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/45,66-71\">",
"     45,66-71",
"    </a>",
"    ], valerian [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/72\">",
"     72",
"    </a>",
"    ], mistletoe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/73\">",
"     73",
"    </a>",
"    ], skullcap [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/72-74\">",
"     72-74",
"    </a>",
"    ], chaparral [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/75-79\">",
"     75-79",
"    </a>",
"    ], comfrey [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/80-84\">",
"     80-84",
"    </a>",
"    ], herbal teas containing toxic alkaloids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/82,85-87\">",
"     82,85-87",
"    </a>",
"    ], pennyroyal oil [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/88\">",
"     88",
"    </a>",
"    ], and kava (",
"    <a class=\"graphic graphic_table graphicRef76400 \" href=\"UTD.htm?8/4/8269\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/60,89-93\">",
"     60,89-93",
"    </a>",
"    ]. Although liver abnormalities are frequently transient, cases of chronic liver disease and acute liver failure have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,12,93,94\">",
"     11,12,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pyrrolizidine alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyrrolizidine alkaloids (PAs) are a group of naturally occurring alkaloids based on the structure of pyrrolizidine. More than 350 PAs have been identified in over 6000 plant species throughout the world (3 percent of the world's flowering plants) (",
"    <a class=\"graphic graphic_table graphicRef61224 \" href=\"UTD.htm?36/16/37133\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. They are used for a variety of complaints, including arthritis, gout, and a number of infections. Their hepatotoxicity, which has been long recognized, is predominantly observed after exposure to the following plant families: Boraginaceae (Heliotropium, Trichodesma, Symphytum [Comfrey]), Compositae (Senecio [Bush Teas], Eupatorium), Crotalaria (Leguminosae), Germander (Teucrium chamaedrys), Greater Celandine (Chelidonium majus), and Scrophul-ariaceae (Castilleja) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/80-82,85-87,97\">",
"     80-82,85-87,97",
"    </a>",
"    ]. While sporadic in Western countries, PA poisoning is nearly endemic in areas where traditional remedies are frequently used (such as Africa and India) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Comfrey has been removed from the market in France, where numerous reports of liver damage have been described. It remains widely available in the United States despite FDA requests to remove comfrey products from the market [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/82,100\">",
"     82,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alkaloid toxicity usually results in moderate to severe liver damage, particularly to the hepatic central vein endothelium. This injury results in hepatic sinusoidal obstruction syndrome (veno-occlusive disease), a progressive form of portal hypertension, which often progresses to hepatic failure, although recovery has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The precise mechanism of hepatic injury is unknown, but appears to result from accumulation of highly reactive electrophilic metabolites produced via the cytochrome P450 enzyme system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,80,88\">",
"     11,80,88",
"    </a>",
"    ]. The increased concentration of P450 enzymes within the hepatic centrilobular region correlates with the changes seen histologically. The damage is compounded by depletion of glutathione [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/9,103\">",
"     9,103",
"    </a>",
"    ]. PAs have also been shown to induce apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonthrombotic luminal occlusion of the small centrilobular veins leads to hepatic congestion and subsequent hemorrhagic parenchymal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,105\">",
"     11,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With acute injury, patients typically present with sudden onset abdominal pain, jaundice, conjugated hyperbilirubinemia and elevated aminotransferases. Hepatomegaly and ascites are common.",
"     </li>",
"     <li>",
"      The subacute and chronic forms are more insidious and may mimic cirrhosis and portal hypertension from other causes. However, histology shows a distinctive pattern of centrilobular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited lesions are generally followed by complete recovery once the offending herb has been discontinued. Approximately one-half of patients with liver toxicity will fall into this category [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/101,106\">",
"     101,106",
"    </a>",
"    ]. More extensive disease can lead to cirrhosis, hepatic failure, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,13,106\">",
"     11,13,106",
"    </a>",
"    ]. The acute form is rapidly fatal in 15 to 20 percent of patients (with worse prognosis in adults compared to children). Approximately 15 percent with acute disease will progress to subacute or chronic injury, succumbing within several years to end stage liver disease. Of the remainder, most develop cirrhosis and portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/25,101,106,107\">",
"     25,101,106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatotoxicity from pyrrolizidine alkaloids is dose-dependent and reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/106\">",
"     106",
"    </a>",
"    ]. Death may occur two weeks to more than two years after poisoning, but patients may recover almost completely if the herb intake is discontinued and liver damage is not severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Germander",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blossoms of germander (Teucrium chamaedrys) have been used for thousands of years for a variety of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/108\">",
"     108",
"    </a>",
"    ]. The herb is said to have choleretic properties, although this has never been scientifically proven. Many reports of liver injury, including acute liver failure, have been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/45,66,67,108,109\">",
"     45,66,67,108,109",
"    </a>",
"    ]. The herb has been removed from the market in France [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Most cases of hepatotoxicity have occurred at the manufacturers' recommended doses (600 to 1600",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Clinical symptoms generally occur after approximately two months of ingestion and include a nonspecific hepatitis, which generally runs a benign course [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11\">",
"     11",
"    </a>",
"    ]. Typical features include anorexia, nausea, abdominal pain, and jaundice associated with a marked elevation in serum aminotransferases.",
"   </p>",
"   <p>",
"    Germander contains toxic alkaloids, the furano-diterpenoids, which are oxidized by the cytochrome P450 3A enzyme system into hepatotoxic reactive metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/66,110\">",
"     66,110",
"    </a>",
"    ]. The toxic metabolites accumulate and covalently bind to cellular proteins, which, in association with the depletion of the free-radical scavenger glutathione, leads to acute centrilobular hepatocyte necrosis in vivo. In vitro studies have revealed progressive apoptosis and cytoskeletal disorganization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/12,110\">",
"     12,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete recovery is usually seen within two to six months after discontinuation of the herb. However, fatal cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/9,11,45,68\">",
"     9,11,45,68",
"    </a>",
"    ], as have more insidious presentations with progression to cirrhosis. Cirrhosis generally develops in patients who have ingested the offending herb for longer periods of time or in larger quantities.",
"   </p>",
"   <p>",
"    Poley (Teucrium polium) is in the same genus as germander, and is used for diabetes (in Israel), gastric complaints (in North Africa), fever (in Italy), and as a poultice (in Spain). It has also been linked to liver injury and acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/71,111\">",
"     71,111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Greater celandine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Greater Celandine (Chelidonium majus) is a member of the poppy family that grows mainly in Europe and Asia, but has been introduced into North America. It is considered a \"cleansing\" herb and is said to stimulate pancreatic enzymes and bile. Therefore, it is often used for hepatobiliary (jaundice, hepatitis, gallbladder) and digestive tract (dyspepsia, gastroenteritis, irritable bowel syndrome, constipation, anorexia, stomach cancer, intestinal polyps) complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/112\">",
"     112",
"    </a>",
"    ]. The plant contains over 20 alkaloids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/112\">",
"     112",
"    </a>",
"    ]. When used orally, it has been implicated in more than a dozen cases of liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/112-119\">",
"     112-119",
"    </a>",
"    ]. The mechanism of hepatotoxicity is unclear, and liver injury shows a female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/120\">",
"     120",
"    </a>",
"    ]. Histologic examination of the involved liver has suggested idiosyncratic hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/114\">",
"     114",
"    </a>",
"    ], although cholestatic hepatitis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. There have been no reports of fatalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chaparral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chaparral (Larrea tridentata) is indigenous to the southwestern United States and is derived from the creosote bush. It is said to have antiamebic, antibacterial, antifungal, and antiviral properties. It is used for diarrhea, cramps, chest pain, upper respiratory tract infections, rheumatism, cutaneous venereal lesions, chronic skin disorders, weight loss, and as a \"liver tonic\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/106\">",
"     106",
"    </a>",
"    ] It is popular among patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chaparral-induced hepatotoxicity typically present with acute hepatitis, consisting of anorexia, nausea, right upper quadrant pain, and jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/75\">",
"     75",
"    </a>",
"    ]. Marked elevation in the serum aminotransferase and bilirubin values may be seen. Alkaline phosphatase may be mildly elevated. Acute hepatocellular injury of varying degrees of severity has been reported, including mild cholestatic hepatitis, severe collapse of parenchymal architecture, and massive liver failure requiring transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. The onset of disease occurs 3 to 52 weeks after the ingestion, and resolves in 1 to 17 weeks in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/75\">",
"     75",
"    </a>",
"    ]. Progression to cirrhosis or acute liver failure requiring liver transplantation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chaparral's presumed therapeutic mechanism of action is secondary to the powerful antioxidant, nordihydroguaiaretic acid, which inhibits the cyclooxygenase and lipoxygenase pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/76\">",
"     76",
"    </a>",
"    ]. How this leads to hepatotoxicity is not understood, but may be related to its estrogenic activity and can be influenced by age, alcohol consumption, viruses, or other medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Atractylis gummifera",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atractylis gummifera is used in the Mediterranean as an antipyretic, emetic, and diuretic, and hepatotoxicity continues to be reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,122,123\">",
"     11,122,123",
"    </a>",
"    ]. The onset of hepatitis is rapid, occurring within hours after ingestion. Acute liver failure is a frequent cause of death. The toxins are believed to inhibit the Krebs cycle and mitochondrial functions, inducing oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pennyroyal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pennyroyal (Mentha pulegium) is a highly toxic agent that can cause both hepatic and neurologic injury. It is frequently used to flavor herbal remedies and teas (particularly mint teas) and is often used for digestive disorders, liver disorders, amenorrhea, gout, colds, increased micturition, and for skin diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/125\">",
"     125",
"    </a>",
"    ]. Less commonly, it is used as an abortifacient. Acute toxicity leads to gastrointestinal distress and CNS effects within one to two hours of ingestion (up to 10 mL of the oil), and fatal ingestions can occur with ingestion of &gt;15 mL of the oil [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The P450-induced oxidative metabolites of the active compound, pulegone, are associated with severe hepatic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/106\">",
"     106",
"    </a>",
"    ]. These metabolites bind to cellular proteins and deplete hepatic glutathione [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/88,127,128\">",
"     88,127,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mistletoe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mistletoe (Viscum album) is purported to be effective in treating asthma, epilepsy, arteriosclerosis, cardiac arrhythmia, cramps, blood loss, nervous conditions, high blood pressure, joint pain, dizziness, infertility, and is used as an aphrodisiac [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/73,125\">",
"     73,125",
"    </a>",
"    ]. There have been case reports of hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/73\">",
"     73",
"    </a>",
"    ]. However, controversy remains as to whether mistletoe actually causes disease. In the reported cases, the ingested capsules were also laced with Skullcap (Scutellaria galericulata). Skullcap and Valerian (Valeriana officinalis) have been implicated in liver injury, although there are no experimental data supporting their toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,13,72\">",
"     11,13,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Kava kava",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kava kava (Piper methysticum) is used as a dietary supplement and has been used in the South Pacific for centuries for complaints of anxiety, sleeplessness, and menopausal symptoms. Numerous reports of severe hepatotoxicity and liver failure have been described in Europe and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/60,89-93,129\">",
"     60,89-93,129",
"    </a>",
"    ]. Hepatotoxicity has been reported within a few weeks to up to two years (average 4.5 months) following ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, reports of toxicity range from transient elevation in aminotransferases to acute liver failure and death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/60\">",
"     60",
"    </a>",
"    ]. Liver injury has been characterized histologically with hepatic necrosis, cholestatic hepatitis and lobular hepatitis. The mechanism of hepatotoxicity is unknown. Based upon case reports of serious toxicity, the United States Food and Drug Administration issued a consumer advisory in November 2002 regarding this toxic herbal product. Details of the advisory are available online (",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm\">",
"     www.cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm",
"    </a>",
"    ). The link of toxicity to Kava kava remains debated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/130\">",
"     130",
"    </a>",
"    ]. Some propose that the aqueous preparation is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/131\">",
"     131",
"    </a>",
"    ], while others have shown that even this preparation leads to hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Camellia sinensis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracts of Camellia sinensis (Chinese green tea) have been associated with hepatocellular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/133-135\">",
"     133-135",
"    </a>",
"    ]. The mechanism is unclear, but a genetic predisposition is probably involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/133,136\">",
"     133,136",
"    </a>",
"    ]. Liver injury generally occurs within three months of use and generally resolves with discontinuation of the product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hydroxycut&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroxycut is a brand name under which many different herbal preparations have been marketed. Used for weight loss and body-building, the first reports of hepatotoxicity following use of Hydroxycut appeared in the literature in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/137-141\">",
"     137-141",
"    </a>",
"    ]. The FDA subsequently issued a warning regarding the product's potential hepatotoxicity and recommended that consumers discontinue use of the products carrying the brand name Hydroxycut [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/142,143\">",
"     142,143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Herbalife&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbalife is another group of substances marketed for multiple uses, including weight management, energy and fitness, and basic and targeted nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/144\">",
"     144",
"    </a>",
"    ]. It has been associated with cases of hepatitis, jaundice, and acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/35,145-149\">",
"     35,145-149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250971751\">",
"    <span class=\"h2\">",
"     Enzyte&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyte is an herbal supplement that contains a group of substances marketed for \"natural male enhancement\". Its use has been associated with acute hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/150\">",
"     150",
"    </a>",
"    ]. It contains multiple herbal supplements including Ginkgo biloba, Epimedium sagittatum, ginseng, Avena sativa (oat bran) extract, maca root, saw palmetto berry, Ptychopetalum olacoides (muira puama extract), octacosanol, L-arginine, Tribulus terrestris extract, pine bark, and Swedish flower pollen. It also contains the minerals niacin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    , and copper.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anabolic steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anabolic steroid use has long been associated with many types of liver injury, including hepatitis, intrahepatic cholestasis, peliosis hepatitis, adenoma, and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/151,152\">",
"     151,152",
"    </a>",
"    ]. They were first identified and synthesized in the 1930s, classified as a class III controlled substance in 1991, and further regulated in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/17\">",
"     17",
"    </a>",
"    ]. Despite their regulation and well-known hepatic toxicity, their use remains widespread, and patients continue to present with hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/153\">",
"     153",
"    </a>",
"    ]. The FDA has issued a public health advisory warning consumers to stop using any body building products that are represented to contain anabolic steroids or steroid-like substances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157890623\">",
"    <span class=\"h2\">",
"     Flavocoxid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/1/24595?source=see_link\">",
"     Flavocoxid",
"    </a>",
"    is a prescription medical food that is a blend of two flavonoids, baicalin and catechins (derived from the plants Scutellaria baicalensis and Acacia catechu, respectively). It is used to treat osteoarthritis. In a prospective study of 877 patients, four patients (0.4 percent) developed liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/155\">",
"     155",
"    </a>",
"    ]. The association between flavocoxid use and liver injury was deemed highly likely in three cases, and possible in one. In all four cases, liver tests returned to normal within 3 to 12 weeks of discontinuing the flavocoxid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHINESE HERBAL REMEDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 7000 species of medicinal plants are used in China with a projected $400 billion market by 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/156\">",
"     156",
"    </a>",
"    ]. Many have beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/27\">",
"     27",
"    </a>",
"    ]. However, hepatotoxicity has been reported with at least 10 species [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/27,60,61,65,157-159\">",
"     27,60,61,65,157-159",
"    </a>",
"    ] and ranges from mild toxic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/157,158\">",
"     157,158",
"    </a>",
"    ] to acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/94\">",
"     94",
"    </a>",
"    ]. It is often difficult to identify the agent responsible for the hepatotoxicity since most Chinese preparations are either concoctions of multiple herbal preparations or have been adulterated with substituted herbs, heavy metals, or Western medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11-13,24,26,28-31\">",
"     11-13,24,26,28-31",
"    </a>",
"    ]. A case of fatal hepatitis has been reported in a patient using a concoction of eight separate herbs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/157\">",
"     157",
"    </a>",
"    ]. Autopsy revealed massive hepatic necrosis, but the offending herb was never definitively identified. Toxicity is generally observed with preparations that contain aconitine, podophyllin, or anticholinergics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Jin Bu Huan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jin Bu Huan (Lycopodium serratum) has been used for over 1000 years as a sedative and analgesic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/61,108,109,125\">",
"     61,108,109,125",
"    </a>",
"    ]. It has morphine-like properties due to the alkaloid levo-tetrahydropalmatine.",
"   </p>",
"   <p>",
"    Both acute and chronic hepatotoxicity have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/61,62,160\">",
"     61,62,160",
"    </a>",
"    ]. Patients with hepatotoxicity present at a mean of 20 weeks after ingestion with acute hepatitis associated with fever, nausea, vomiting, fatigue, pruritus, abdominal pain, hepatomegaly, and jaundice. Plasma aminotransferase levels are significantly elevated. The liver biopsies that have been performed appear consistent with a drug-induced liver injury, demonstrating eosinophils and focal hepatocellular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms resolve with discontinuation of herb (mean eight weeks) and have promptly recurred when patients were rechallenged [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The hepatotoxic mechanism is not known but may be immunologic given the histologic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ma-Huang (ephedra)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ma-Huang (Ephedra sinica), an ephedra alkaloid, has been used for centuries for cough, bronchitis, fever, joint symptoms, edema, bone pain, to induce weight loss, and as a CNS stimulant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/63,65,125\">",
"     63,65,125",
"    </a>",
"    ]. The active ingredient is ephedrine. Ephedrine is not known to be hepatotoxic per se, but reports of hepatotoxicity have been associated with use of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/63-65,161\">",
"     63-65,161",
"    </a>",
"    ]. The mechanism of toxicity is not known.",
"   </p>",
"   <p>",
"    Affected patients presented in similar fashion to those taking Jin Bu Huan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. Biopsies revealed diffuse severe hepatocellular necrosis, and polymorphonuclear cell infiltrates with occasional eosinophils. Abnormal tests resolved within four months of discontinuation of drug. Ephedra has been withdrawn from the United States market.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Syo-saiko-to",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syo-saiko-to (xiao-chai-hu-tang, da-chai-hu-tang, TJ-9) contains numerous herbal products (Bupleuri root, Pinelliae tuber, Scutellaria root, ginseng root, ginger rhizome, glycyrrhiza root, and jujube fruit), and is being used increasingly in the treatment of hepatitis C virus infection. There have been reports of hepatotoxicity associated with this product [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. Patients should be cautioned against using this herbal remedy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER HEPATOTOXIC HERBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many case reports of hepatotoxicity with other herbal preparations. These include Bajiaolian, Borage (Borago officinalis), Broom Corn (Sorghum vulgare), Callilepsis laureola, Camphor, Centella asiatica (gotu kola), Margosa oil (Azadirachza indica), Cocaine, Coltsfoot, Copaltra (Coutarea latiflora and Centaurium erythraea), Kombucha tea, LipoKinetix (a capsule used for weight loss that contains multiple ingredients including usnic acid from the lichen Usnea barbata), Noni (Morinda citrifolia), Cascara sagrada, Sassafras (Sassafras albidum),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     Senna",
"    </a>",
"    (Cassia angustifolia), Chaso, and Onshido (weight loss compounds containing several ingredients) and \"Herbalife\" (a supplement used for promoting wellness and weight loss) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/2/25642/abstract/11,13,25,60,106,108,109,113,145,146,164-176\">",
"     11,13,25,60,106,108,109,113,145,146,164-176",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herbal remedies may be associated with hepatotoxicity, making it important to discuss the use of herbal and dietary supplements (HDS) and complementary and alternative medical (CAM) therapies in an attempt to prevent potential complications, such as herb-drug interactions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"       \"Overview of herbal medicine and dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of herbal remedies should be considered as a possible etiology in any setting of clinical manifestations of liver injury.",
"     </li>",
"     <li>",
"      Proving that an herbal or dietary supplement causes liver injury relies on both chronological and clinical criteria. Features suggesting drug toxicity include lack of illness prior to ingesting the drug, clinical illness or biochemical abnormalities developing after beginning the drug, and improvement after the product is withdrawn. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining a sample of the implicated HDS or CAM therapies for testing is possible, but expertise is not widely available. Costs are generally prohibitive, and most research laboratories are capable of testing only for certain compounds.",
"     </li>",
"     <li>",
"      The mainstay of therapy for herbal hepatotoxicity is withdrawal of the offending toxin and supportive care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A",
"      <a class=\"external\" href=\"file://www.livertox.nih.gov/\">",
"       searchable database",
"      </a>",
"      of drugs, herbal medications, and dietary supplements has been developed by the National Institutes of Health.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/1\">",
"      Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     Complementary and Alternative Medicine in the United States. Institute of Medicine Committee on the Use of Complementary and Alternative Medicine by the American Public; National Academies Press (US), Washington (DC), 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/3\">",
"      Saydah SH, Eberhardt MS. Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. J Altern Complement Med 2006; 12:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/4\">",
"      Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/5\">",
"      Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; May 27;(343):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/6\">",
"      American Botanical Council. Herbal Supplement Sales Experience Slight Increase in 2008. Herbal Gram 2009; 82:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/7\">",
"      Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002; 40:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/8\">",
"      Graham RE, Ahn AC, Davis RB, et al. Use of complementary and alternative medical therapies among racial and ethnic minority adults: results from the 2002 National Health Interview Survey. J Natl Med Assoc 2005; 97:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/9\">",
"      Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30:1099.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow J. Nature's medicine. Plants that heal. 2000 Nat'l Geographic Society.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/11\">",
"      Larrey D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis 1995; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/12\">",
"      Kaplowitz N. Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death. Gastroenterology 1997; 113:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/13\">",
"      Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/14\">",
"      Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001; 135:344.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.livertox.nih.gov/ (Accessed on October 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/16\">",
"      Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001; 135:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/17\">",
"      Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 29:373.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for consumers: Dietary supplements. US Food and Drug Administration. file://www.fda.gov/Food/DietarySupplements/ConsumerInformation/default.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     Federal Food, Drug, and Cosmetic Act (FD&amp;C) Act file://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     United States Pharmacopeia (USP). About USP - an overview file://www.usp.org/aboutUSP (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Center for Food Safety and Applied Nutrition. Dietary Supplements file://www.fda.gov/Food/DietarySupplements/default.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Claims that can be made for conventional foods and dietary supplements file://www.fda.gov/Food/LabelingNutrition/LabelClaims/ucm111447.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Guidance, Compliance &amp; Regulatory Information file://www.fda.gov/food/DietarySupplements/GuidanceComplianceRegulatoryInformation (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/24\">",
"      Tomlinson B, Chan TY, Chan JC, et al. Toxicity of complementary therapies: an eastern perspective. J Clin Pharmacol 2000; 40:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/25\">",
"      Cole MR, Fetrow CW. Adulteration of dietary supplements. Am J Health Syst Pharm 2003; 60:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/26\">",
"      Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002; 23:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/27\">",
"      Chan TY, Chan JC, Tomlinson B, Critchley JA. Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 1993; 342:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/28\">",
"      Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998; 339:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/29\">",
"      Chan TY, Critchley JA. Usage and adverse effects of Chinese herbal medicines. Hum Exp Toxicol 1996; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/30\">",
"      Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997; 37:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/31\">",
"      Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002; 252:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/32\">",
"      Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995; 333:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/33\">",
"      Gertner E, Marshall PS, Filandrinos D, et al. Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs. Arthritis Rheum 1995; 38:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/34\">",
"      Kang-Yum E, Oransky SH. Chinese patent medicine as a potential source of mercury poisoning. Vet Hum Toxicol 1992; 34:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/35\">",
"      Stickel F, Droz S, Patsenker E, et al. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol 2009; 50:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/36\">",
"      Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005; 27:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/37\">",
"      Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008; 300:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/38\">",
"      Kales SN, Christophi CA, Saper RB. Hematopoietic toxicity from lead-containing Ayurvedic medications. Med Sci Monit 2007; 13:CR295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/39\">",
"      Seeff LB, Lindsay KL, Bacon BR, et al. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/40\">",
"      Koff RS. Herbal hepatotoxicity. Revisiting a dangerous alternative. JAMA 1995; 273:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/41\">",
"      Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/42\">",
"      Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/43\">",
"      Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/44\">",
"      Zimmerman HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/45\">",
"      Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/46\">",
"      Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/47\">",
"      Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009; 29:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/48\">",
"      B&eacute;nichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272.",
"     </a>",
"    </li>",
"    <li>",
"     USFDA Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     Navaro V. Hepatic adverse event nomenclature document file://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm080336.htm (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/51\">",
"      Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/52\">",
"      Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/53\">",
"      Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/54\">",
"      Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/55\">",
"      Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/56\">",
"      O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/57\">",
"      Bj&ouml;rnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/58\">",
"      Reuben A. Hy's law. Hepatology 2004; 39:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/59\">",
"      Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf 1997; 17:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/60\">",
"      Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/61\">",
"      Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994; 121:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/62\">",
"      Picciotto A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/63\">",
"      Neff GW, Reddy KR, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004; 41:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/64\">",
"      Bajaj J, Knox JF, Komorowski R, Saeian K. The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig Dis Sci 2003; 48:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/65\">",
"      Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 1996; 91:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/66\">",
"      Lekehal M, Pessayre D, Lereau JM, et al. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 1996; 24:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/67\">",
"      Lalibert&eacute; L, Villeneuve JP. Hepatitis after the use of germander, a herbal remedy. CMAJ 1996; 154:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/68\">",
"      Mostefa-Kara N, Pauwels A, Pines E, et al. Fatal hepatitis after herbal tea. Lancet 1992; 340:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/69\">",
"      Castot A, Larrey D. [Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance]. Gastroenterol Clin Biol 1992; 16:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/70\">",
"      Castot A, Djezzar S, Deleau N, et al. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants]. Therapie 1997; 52:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/71\">",
"      Mimidis KP, Papadopoulos VP, Baltatzidis G, et al. Severe acute cholestasis caused by Teucrium polium. J Gastrointestin Liver Dis 2009; 18:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/72\">",
"      MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989; 299:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/73\">",
"      Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed) 1981; 282:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/74\">",
"      Hullar TE, Sapers BL, Ridker PM, et al. Herbal toxicity and fatal hepatic failure. Am J Med 1999; 106:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/75\">",
"      Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997; 157:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/76\">",
"      Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/77\">",
"      Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995; 273:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/78\">",
"      Smith BC, Desmond PV. Acute hepatitis induced by ingestion of the herbal medication chaparral. Aust N Z J Med 1993; 23:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/79\">",
"      Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995; 90:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/80\">",
"      Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989; 87:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/81\">",
"      Ridker PM, McDermott WV. Comfrey herb tea and hepatic veno-occlusive disease. Lancet 1989; 1:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/82\">",
"      Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987; 295:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/83\">",
"      Yeong ML, Swinburn B, Kennedy M, Nicholson G. Hepatic veno-occlusive disease associated with comfrey ingestion. J Gastroenterol Hepatol 1990; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/84\">",
"      Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr 2000; 3:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/85\">",
"      Kumana CR, Ng M, Lin HJ, et al. Herbal tea induced hepatic veno-occlusive disease: quantification of toxic alkaloid exposure in adults. Gut 1985; 26:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/86\">",
"      Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Prod 1981; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/87\">",
"      Mattocks AR. Toxicity of pyrrolizidine alkaloids. Nature 1968; 217:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/88\">",
"      Gordon WP, Forte AJ, McMurtry RJ, et al. Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol Appl Pharmacol 1982; 65:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/89\">",
"      Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. MMWR Morb Mortal Wkly Rep 2002; 51:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/90\">",
"      Ernst E. Safety concerns about kava. Lancet 2002; 359:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/91\">",
"      Wooltorton E. Herbal kava: reports of liver toxicity. CMAJ 2002; 166:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/92\">",
"      Campo JV, McNabb J, Perel JM, et al. Kava-induced fulminant hepatic failure. J Am Acad Child Adolesc Psychiatry 2002; 41:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/93\">",
"      Gow PJ, Connelly NJ, Hill RL, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/94\">",
"      Yoshida EM, McLean CA, Cheng ES, et al. Chinese herbal medicine, fulminant hepatitis, and liver transplantation. Am J Gastroenterol 1996; 91:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/95\">",
"      Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007; 11:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/96\">",
"      Stegelmeier BL, Edgar JA, Colegate SM, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins 1999; 8:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/97\">",
"      Pearson W. Pyrrolizidine alkaloids in higher plants: hepatic veno-occlusive disease associated with chronic consumption. J Neutraceuticals 2000; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/98\">",
"      Steenkamp V, Stewart MJ, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit 2000; 22:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/99\">",
"      Tandon HD, Tandon BN, Ramalingaswami V. Epidemic of toxic hepatitis in India of possible mycotoxic origin. Arch Pathol Lab Med 1978; 102:372.",
"     </a>",
"    </li>",
"    <li>",
"     FDA advises dietary supplement manufacturers to remove comfrey products from the market file://www.fda.gov/Food/DietarySupplements/Alerts/ucm111219.htm (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/101\">",
"      Conradie J, Stewart MJ, Steenkamp V. GC/MS identification of toxic pyrrolizidine alkaloids in traditional remedies given to two sets of twins. Ann Clin Biochem 2005; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/102\">",
"      Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis 2012; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/103\">",
"      Neuman MG, Jia AY, Steenkamp V. Senecio latifolius induces in vitro hepatocytotoxicity in a human cell line. Can J Physiol Pharmacol 2007; 85:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/104\">",
"      Ji LL, Zhang M, Sheng YC, Wang ZT. Pyrrolizidine alkaloid clivorine induces apoptosis in human normal liver L-02 cells and reduces the expression of p53 protein. Toxicol In Vitro 2005; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/105\">",
"      Valla D, Benhamou JP. Drug-induced vascular and sinusoidal lesions of the liver. Baillieres Clin Gastroenterol 1988; 2:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/106\">",
"      Schiano TD. Liver injury from herbs and other botanicals. Clin Liver Dis 1998; 2:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/107\">",
"      Ridker PM, Ohkuma S, McDermott WV, et al. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/108\">",
"      Bateman J, Chapman RD, Simpson D. Possible toxicity of herbal remedies. Scott Med J 1998; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/109\">",
"      Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol 1997; 12:S242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/110\">",
"      Fau D, Lekehal M, Farrell G, et al. Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997; 113:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/111\">",
"      Matt&eacute;i A, Rucay P, Samuel D, et al. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol 1995; 22:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/112\">",
"      Moro PA, Cassetti F, Giugliano G, et al. Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 2009; 124:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/113\">",
"      Stickel F, P&ouml;schl G, Seitz HK, et al. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003; 38:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/114\">",
"      Benninger J, Schneider HT, Schuppan D, et al. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/115\">",
"      Crijns AP, de Smet PA, van den Heuvel M, et al. [Acute hepatitis after use of a herbal preparation with greater celandine (Chelidonium majus)]. Ned Tijdschr Geneeskd 2002; 146:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/116\">",
"      De Smet PA. Safety concerns about kava not unique. Lancet 2002; 360:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/117\">",
"      Greving I, Meister V, Monnerjahn C, et al. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Saf 1998; 7 Suppl 1:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/118\">",
"      Rifai K, Flemming P, Manns MP, et al. Severe drug hepatitis caused by Chelidonium. 2006; Internist 47:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/119\">",
"      Teschke R, Glass X, Schulze J, Eickhoff A. Suspected Greater Celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol 2012; 24:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/120\">",
"      Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/121\">",
"      Kassler WJ, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med 1991; 151:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/122\">",
"      Zaim N, Guemouri L, Lamnaouer D, Benjouad A. [Study of four cases of poisoning by Atractylis gummifera L. in Morocco]. Therapie 2008; 63:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/123\">",
"      Skalli S, Alaoui I, Pineau A, et al. [Atractylis gummifera L. poisoning: a case report]. Bull Soc Pathol Exot 2002; 95:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/124\">",
"      Obatomi DK, Brant S, Anthonypillai V, Bach PH. Toxicity of atractyloside in precision-cut rat and porcine renal and hepatic tissue slices. Toxicol Appl Pharmacol 1998; 148:35.",
"     </a>",
"    </li>",
"    <li>",
"     Gruenwald J, Brendler T, Jaenicke C. Pennyroyal. In: PDR for Herbal Medicines, second edition, Medical Economics Company, New Jersey 2000. p.579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/126\">",
"      Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/127\">",
"      Bakerink JA, Gospe SM Jr, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 1996; 98:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/128\">",
"      Thomassen D, Slattery JT, Nelson SD. Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther 1990; 253:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/129\">",
"      Stickel F, Baum&uuml;ller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/130\">",
"      Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/131\">",
"      Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009; 205:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/132\">",
"      Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 2009; 123:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/133\">",
"      Javaid A, Bonkovsky HL. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol 2006; 45:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/134\">",
"      Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006; 144:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/135\">",
"      Molinari M, Watt KD, Kruszyna T, et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006; 12:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/136\">",
"      Weinstein DH, Twaddell WS, Raufman JP, et al. SlimQuick&trade; - associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity. World J Hepatol 2012; 4:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/137\">",
"      Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med 2005; 142:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/138\">",
"      Jones FJ, Andrews AH. Acute liver injury associated with the herbal supplement hydroxycut in a soldier deployed to Iraq. Am J Gastroenterol 2007; 102:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/139\">",
"      Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008; 14:6999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/140\">",
"      Shim M, Saab S. Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci 2009; 54:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/141\">",
"      Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010; 105:1561.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Warning on Hydroxycut products file://www.fda.gov/ForConsumers/ConsumerUpdates/ucm152152.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Warns Consumers to Stop Using Hydroxycut Products file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149575.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     Herbalife Website file://www.herbalife.com (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/145\">",
"      Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/146\">",
"      Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007; 47:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/147\">",
"      Duque JM, Ferreiro J, Salgueiro E, Manso G. [Hepatotoxicity associated with the consumption of herbal slimming products]. Med Clin (Barc) 2007; 128:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/148\">",
"      Chao S, Anders M, Turbay M, et al. [Toxic hepatitis by consumption Herbalife products a case report]. Acta Gastroenterol Latinoam 2008; 38:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/149\">",
"      Manso G, L&oacute;pez-Rivas L, Duque JM, Salgueiro E. Spanish reports of hepatotoxicity associated with Herbalife products. J Hepatol 2008; 49:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/150\">",
"      Ramanathan VS, Mitropoulos E, Shlopov B, et al. An Enzyte'ing' case of acute hepatitis. J Clin Gastroenterol 2011; 45:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/151\">",
"      Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981; 1:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/152\">",
"      Hepatic effects of 17 alpha-alkylated anaboli-androgenic steroids. HIV Hotline 1998; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/153\">",
"      Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007; 5:809.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Body Building Products Marketed as Containing Steroids or Steroid-Like Substances file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173965.htm (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/155\">",
"      Chalasani N, Vuppalanchi R, Navarro V, et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 2012; 156:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/156\">",
"      Wang ZG, Ren J. Current status and future direction of Chinese herbal medicine. Trends Pharmacol Sci 2002; 23:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/157\">",
"      Perharic-Walton L, Murray V. Toxicity of Chinese herbal remedies. Lancet 1992; 340:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/158\">",
"      Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet 1992; 340:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/159\">",
"      Jung KA, Min HJ, Yoo SS, et al. Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb. Gut Liver 2011; 5:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/160\">",
"      Horowitz RS, Feldhaus K, Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996; 156:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/161\">",
"      Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 2001; 96:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/162\">",
"      Itoh S, Marutani K, Nishijima T, et al. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci 1995; 40:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/163\">",
"      Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997; 92:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/164\">",
"      Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/165\">",
"      Perron AD, Patterson JA, Yanofsky NN. Kombucha \"mushroom\" hepatotoxicity. Ann Emerg Med 1995; 26:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/166\">",
"      Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002; 136:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/167\">",
"      Nadir A, Reddy D, Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. Am J Gastroenterol 2000; 95:3634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/168\">",
"      Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido. Ann Intern Med 2003; 139:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/169\">",
"      Kao WF, Hung DZ, Tsai WJ, et al. Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics. Hum Exp Toxicol 1992; 11:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/170\">",
"      Uc A, Bishop WP, Sanders KD. Camphor hepatotoxicity. South Med J 2000; 93:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/171\">",
"      Mallat A, Dhumeaux D. Cocaine and the liver. J Hepatol 1991; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/172\">",
"      Wurtz AS, Vial T, Isoard B, Saillard E. Possible hepatotoxicity from Copaltra, an herbal medicine. Ann Pharmacother 2002; 36:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/173\">",
"      Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 2005; 17:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/174\">",
"      Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev Esp Enferm Dig 2005; 97:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/175\">",
"      Beuers U, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet 1991; 337:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/2/25642/abstract/176\">",
"      Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65:331.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3618 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25642=[""].join("\n");
var outline_f25_2_25642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H235294330\">",
"      DATABASE OF DRUGS, HERBS, AND SUPPLEMENTS ASSOCIATED WITH HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FREQUENCY OF HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECIFIC HEPATOTOXIC HERBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pyrrolizidine alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Germander",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Greater celandine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chaparral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Atractylis gummifera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pennyroyal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mistletoe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Kava kava",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Camellia sinensis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hydroxycut&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Herbalife&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250971751\">",
"      Enzyte&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anabolic steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H157890623\">",
"      Flavocoxid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHINESE HERBAL REMEDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Jin Bu Huan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ma-Huang (ephedra)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Syo-saiko-to",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER HEPATOTOXIC HERBS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/31/19963\" title=\"table 1\">",
"      Complementary therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/32/3595\" title=\"table 2\">",
"      Classification of liver test abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/23/23934\" title=\"table 3\">",
"      Drug reactions RUCAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8269\" title=\"table 4\">",
"      Herbal medicine hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/16/37133\" title=\"table 5\">",
"      Pyrrolizidine alkaloids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_2_25643="Criteria obsessive personality";
var content_f25_2_25643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for obsessive-compulsive personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of the following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Is preoccupied with details, rules, lists, order, organization, or schedules to the extent that the major point of the activity is lost",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Shows perfectionism that interferes with task completion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Is excessively devoted to work and productivity to the exclusion of leisure activities and friendships",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Is overconscientious, scrupulous, and inflexible about matters of morality, ethics, or values (not accounted for by cultural or religious identification)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Is unable to discard worn-out or worthless objects even when they have no sentimental value",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Is reluctant to delegate tasks or to work with others unless they submit to exactly his or her way of doing things",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Adopts a miserly spending style toward both self and others; money is viewed as something to be hoarded for future catastrophes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. Shows rigidity and stubbornness",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25643=[""].join("\n");
var outline_f25_2_25643=null;
var title_f25_2_25644="Allergen avoidance trials";
var content_f25_2_25644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Controlled trials of allergen avoidance that have achieved prolonged decrease in mite allergen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Authors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Avoidance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active/controls",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decrease in mite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary outcome(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Murray, AB, Ferguson, AC;",
"        </p>",
"        <p>",
"         Pediatrics 1983; 71:418",
"        </p>",
"       </td>",
"       <td>",
"        1 yr",
"       </td>",
"       <td>",
"        Physical barriers",
"       </td>",
"       <td>",
"        10/10",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        BHR**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Carswell et al.;",
"        </p>",
"        <p>",
"         Clin Exp Allergy 1996; 26:386",
"        </p>",
"       </td>",
"       <td>",
"        6 mos",
"       </td>",
"       <td>",
"        Physical barriers + Acarosan",
"       </td>",
"       <td>",
"        24/25",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        <p>",
"         Peak flow&bull;",
"        </p>",
"        <p>",
"         BHR&bull;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Ehnert, B, et al.;",
"        </p>",
"        <p>",
"         J Allergy Clin Immunol 1992; 90:135",
"        </p>",
"       </td>",
"       <td>",
"        1 yr",
"       </td>",
"       <td>",
"        Physical barriers + tannic acid",
"       </td>",
"       <td>",
"        8/16",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        BHR**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Walshaw, MJ, Evans, CC;",
"        </p>",
"        <p>",
"         Q J Med 1986; 58:199",
"        </p>",
"       </td>",
"       <td>",
"        1 yr",
"       </td>",
"       <td>",
"        Physical barriers",
"       </td>",
"       <td>",
"        22/20",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        PEFR/BHR**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Halken et al.;",
"        </p>",
"        <p>",
"         J Allergy Clin Immunol 1997; 99:S320",
"        </p>",
"       </td>",
"       <td>",
"        1 yr",
"       </td>",
"       <td>",
"        Physical barriers",
"       </td>",
"       <td>",
"        28/24",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        PEFR**BHR*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Htut, T, et al.;",
"        </p>",
"        <p>",
"         J Allergy Clin Immunol 2001; 107:55.",
"        </p>",
"       </td>",
"       <td>",
"        1 yr",
"       </td>",
"       <td>",
"        Dry heat and steam cleaning",
"       </td>",
"       <td>",
"        20/10",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        BHR*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Improvement: ** Highly significant; * Significant; &bull; improved but not significant.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25644=[""].join("\n");
var outline_f25_2_25644=null;
var title_f25_2_25645="SAECG predicts atrial fibrillation post CABG";
var content_f25_2_25645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Signal averaged electrocardiogram predicts atrial fibrillation after coronary artery bypass graft (CABG) surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence of atrial fibrillation (AF) after coronary artery bypass graft surgery is directly related to the duration of the P wave on a signal averaged ECG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Zaman AG, Archbold RA, Helft G, et al. Circulation 2000; 101:1403.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25645=[""].join("\n");
var outline_f25_2_25645=null;
var title_f25_2_25646="Arm volumeter instructions";
var content_f25_2_25646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Home arm volumeter instructions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        I. How to construct a home arm volumeter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A. Parts. All parts are made of common polyvinyl chloride (PVC) piping used in plumbing. All parts are unthreaded. (Note: Phrases set in quotation marks in this section indicate the phrase to use when purchasing materials at the hardware store.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        one 6-inch (15-cm) internal diameter PVC pipe of approximately 1/4-inch (6-mm) standard thickness (called \"6-inch Pipe\"); length equal to arm length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        one 4-inch (10-cm) internal diameter PVC pipe (called \"4-inch Pipe\"), 9 inches (23 cm) long",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        one asymmetric \"Y\" PVC all female connector (called \"Asymmetric Y connector\"; also called \"Wye\" in some plumbing catalogs), designed to connect two 6-inch and one 4-inch pipes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        one PVC 45-degree elbow (called \"Elbow\") with one male and one female connecter end, designed to connect two 4-inch-diameter PVC pipes, also called a \"45-degree 4-inch male-female PVC angle\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        one 6-inch PVC cap (called \"6 inch Cap\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PVC solvent glue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        B. Assembly instructions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        1. Arm length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Determine arm length by measuring the arm from the inner fold of the armpit (anterior axillary fold; Point A) along the inside (anterior aspect) of the arm to the tip of the middle finger when the hand is outstretched in a taut position (Point B).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        2. Cutting and gluing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Warning: It is dangerous to cut PVC pipe with a power saw and to handle PVC glue, which emits toxic vapors; these tasks should be left to a properly trained person.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Reference for metric equivalents: Conversion factor: 1 inch = 2.5 cm. Approximate equivalents: 1/4 inch = 6 mm; 4 inches = 10 cm; 5 inches = 13 cm; 6 inches = 15 cm; 9 inches = 23 cm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Cut the 6-inch pipe to a length equal the length of the arm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Cut the 4-inch pipe to a length of 9 inches (23 cm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Cut the asymmetric Y-connector. Stand the asymmetric Y-connector with the 4-inch connector end facing down. Measure 5 inches (13 cm) up from the bottom of the 6-inch connector end and mark point A. Mark point B just above the ridge of the 4-inch connector end (Step 1). Cut across the asymmetric Y-connector in a straight line spanning from point A to point B (Step 2). File and sand the newly cut top edge to make a smooth, curved lip (Step 3).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Glue the 6-inch cap to one end of the 6-inch pipe to seal the bottom of the volumeter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e. Glue the asymmetric Y-connector to the other end of the 6-inch pipe.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        3. Fitting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Attach the 4-inch pipe to one end of the elbow and attach the elbow to the asymmetric Y-connector. The volumeter's spout is now in place. The spout also serves as a handle to lift, drag, or carry the volumeter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        C. Filing, sanding, cleaning, and disinfecting. Clean all parts before assembly. Carefully check the assembled volumeter, inside and out. File and sand any sharp edges or points. Clean and disinfect the volumeter using a bleach solution. Rinse thoroughly with water to remove any trace of bleach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        II. How to measure arm volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A. Equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Home arm volumeter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beverage pitcher (the pitcher does not need to have volume gradations because the water volume is measured by weighing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digital gram kitchen scale or postal scale (the scale should read up to 5000 grams, be accurate to 1 gram, and have a platform large enough to hold the pitcher. The display must be in grams [not ounces] because water weight in grams is equivalent to water volume in milliliters, which is the only way the water volume can be determined through weighing. The author strongly recommends that patients weigh the water and not use graduated containers, which are too imprecise and yield misleading volumetric readings.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        B. Measurement procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Weigh the empty pitcher and record its empty weight (Step 1). This will be a constant that you always subtract from the weight of the pitcher of water.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Place the volumeter on a level-surfaced floor. To achieve comparable measurements, try to place the volumeter in the same location each time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Prepare a comfortable seat beside the volumeter, for example, a stool or low chair. A closed toilet seat may also be convenient with the volumeter placed beside the toilet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Place the pitcher under the volumeter spout. Under the pitcher, place any type of flat base, such as a plastic food storage container, to raise the pitcher up to the edge of the spout. This base is necessary so that no drops of water splash outside of the pitcher (Step 2).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Fill the volumeter with lukewarm water until it overflows into the pitcher. Wait for all air bubbles to settle. Top off the water level with a bit more water and wait for the overflow to completely stop dripping into the pitcher (Step 3).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Empty the water out of the pitcher (Step 4). Dry the pitcher with a towel. Return the dry pitcher to its original spot under the spout of the volumeter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. You are now ready to measure your arm volume. Sit beside the volumeter. Slowly and gently lower your arm into the volumeter. Water will rush out through the spout into the pitcher. Continue lowering your arm until your middle finger touches the bottom of the volumeter, while keeping your fingers, wrist, and elbow in a fully extended and taut position (Step 5).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Hold this position until the water stops dripping into the pitcher. You can best see this by watching when the water in the pitcher becomes still.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9. Remove your arm and dry it with a towel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10. Place the pitcher filled with the overflow water on the scale (Step 6).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11. Record the gram output showing on the scale. From this number, subtract the weight of the empty pitcher (Step 1). The difference equals the volume in grams of the water in the pitcher. This amount equals the volume in millilitres of your arm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12. We recommend that you do at least two consecutive measurements, and preferably&nbsp;three (see Helpful Hints).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13. When you have finished measuring, the volumeter can be dragged or lifted by the spout and tipped into the bathtub or shower to empty.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Helpful hints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The most important procedure in measuring arm volume is Procedure 8: holding the arm immobile in the volumeter until the water stops dripping. This may take up to&nbsp;one minute. It is therefore important to be comfortable and relaxed when you take your arm measurement. Your seat should be comfortable. To avoid straining your back, try to bend from the waist and keep your back straight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measuring in the bathtub: since the floor of the bathtub is not a level surface, it may not be an ideal location for the volumeter. Also, sitting on the side of a bathtub (in a straddle or side-saddle position) is not usually comfortable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        We recommend that you take three measurements in a row and calculate the average, in case of an erratic measurement. By comparing three measurements, you can judge your skill at measurement. With practice, your measurements may vary by less than 10 mililiters, which is highly precise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you discover that the six-inch pipe has been cut too long and your middle finger does not touch bottom before the top of the volumeter hits your armpit, you can use a \"landmark,\" such as a freckle on your upper arm, and stop immersion at that landmark. You can also add a \"false bottom\" to your volumeter by filling a plastic container with vase gems, marbles, or polished stones and placing the weighted container in the volumeter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To lower costs of making the volumeter, patients can group together to have several made at one time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        We recommend that you not modify the design of the home use volumeter. It is the result of trial and error and numerous prototypes over&nbsp;two years. Even a minor design change may change the volume and shape of the water meniscus at the top of the cylinder of water and result in unreliable measurements.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lette J. A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24:5434. Copyright &copy;2006 The American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25646=[""].join("\n");
var outline_f25_2_25646=null;
var title_f25_2_25647="Lifetime risk CVD at age 50";
var content_f25_2_25647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Lifetime risk of cardiovascular disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 377px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative lifetime incidence of cardiovascular disease, adjusted for the competing risk of death, according to the aggregate risk factor (RF) burden in men and women in the Framingham Heart Study at age 50 who did not have clinical cardiovascular disease. The lifetime risk ranged from 5 percent in men and 8 percent in women with all optimal risk factors to 69 percent in men and 50 percent in women with &ge;2 major risk factors. Intermediate values were obtained in patients with intermediate risk factor burdens. The definitions of optimal, not optimal, and major risk factors are presented in the text.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lloyd-Jones, DM, Leip. EP, Larson, MG et al, Circulation 2006; 113:791.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_2_25647=[""].join("\n");
var outline_f25_2_25647=null;
